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Humankind has not woven the web of life. 
We are but one thread within it. 
Whatever we do to the web, we do to ourselves. 
All things are bound together. 
All things connect. 
Chief Seattle, 1854 
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ABSTRACT 
Cerebral ischaemia, traumatic injury to the brain, inflammatory neurological 
disorders and HIV infections are amongst the most prevalent causes of 
neurodegeneration. Neuroprotective strategies are usually to limit the 
progressive secondary injury that generally occurs, thus limiting overall 
tissue damage. 
 
Neuroprotective strategies are usually to limit the progressive secondary 
injury that generally occurs, thus limiting overall tissue damage. Sodium 
channel blockers have been often used for this matter as they prevent the 
cascade of events culminating in free radical generation and eventually 
neuronal apoptosis. Newer compounds, such as antiperoxidants and free 
radical scavengers, show encouraging experimental results, but their clinical 
use is still very limited.  
 
Phenytoin being a popular drug in the treatment of epilepsy has also been 
used as a neuroprotectant during certain neurological emergencies and in 
pharmacological prophylaxis of post-traumatic epilepsy. Furthermore this 
agent functions by prolonging inactivation of voltage gated sodium 
channels. In these sets of experiment the neuroprotective properties of 
phenytoin were examined. 
 
The histological study revealed that phenytoin confers protection to the CA1 
and CA3 regions of the hippocampus under the insult of QUIN. Cells 
maintain their characteristic shape and minimal tissue necrosis occurs in the 
presence of this agent. 
 
 iii
The in vitro effect of this antiepileptic drug on free radicals generation 
shows that phenytoin does not reduce or prevent the formation of these 
reactive species. Lipid peroxidation was induced using QUIN and iron (II), 
two known neurotoxins. The study reveals that only lipid peroxidation 
induced using iron (II) is reduced by phenytoin. These experiments were 
carried out in whole rat brain homogenate. These studies show that 
phenytoin possesses poor free radical scavenging properties. However, the 
dose-related reduction of iron-induced lipid peroxidation allows for 
speculation that phenytoin interacts with iron in order to reduce neuronal 
damage. 
 
Metal binding studies were performed using UV, IR and electrochemical 
analysis to examine the interaction of phenytoin with iron (II) and iron (III). 
Phenytoin, when added to iron (II) in solution, first oxidises the latter to iron 
(III) and maintains it in that form. A shift in the peak was observed in the 
UV spectrum when iron was added to phenytoin. Moreover, electrochemical 
studies indicate that the interaction between the metal and the ligand is very 
weak. The IR analysis it shows that phenytoin may be coordinating with iron 
through the Nitrogen atom on the phenytoin molecule. These studies show 
that phenytoin maintains iron in its oxidised form, which is a good property 
to possess as a neuroprotectants. 
 
 iv
Pineal organ culture showed that phenytoin does not increase melatonin 
production but slightly and non-significantly reduces the levels of this pineal 
hormone. However there is a significant rise in precursor NAS levels. As 
melatonin is known to possess antioxidant and free radical scavenging 
properties, this could mean that this drug can cause the CNS to become more 
susceptible to attacks by reactive oxygen species. 
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CHAPTER 1 
LITERATURE REVIEW 
1.  INTRODUCTION 
1.1. PHENYTOIN 
1.1.1. HISTORY OF PHENYTOIN 
Phenytoin (5,5-diphenylhydantoin) was first synthesised in 1908 by the 
German chemist Heinrich Biltz. He sold phenytoin along with other 
compounds to the company Parke - Davis. The company did not patent it, 
nor did they find a use for it. As a result, phenytoin was forgotten for 
twenty-nine years. 
 
In 1937, Putnam and Merritt, two doctors outside Parke - Davis, discovered 
phenytoin's first clinical use, in epilepsy. This discovery had an extremely 
important impact on the treatment of epilepsy; in fact phenytoin proved to be 
superior to phenobarbital in treating epilepsy and at the same time became 
the first anticonvulsive drug not to cause sedation. This therapeutic property 
of phenytoin is still used at present with its principle application being the 
cases of Grand Mal epilepsy and tonic-clonic seizures. Another major 
application of phenytoin is in its pronounced antiarrhythmic property and 
phenytoin is especially indicated for the treatment of ventricular 
arrhythmias, and more precisely of the arrhythmias caused by digitalis 
toxicity and by acute myocardial infarction. 
 
Both above-mentioned applications are due to phenytoin’s ability to stabilize 
the cellular membranes by means of decreasing sodium conductivity through 
the sodium channels of these membranes. But these properties do not 
 1
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represent the whole broad spectrum of its clinical usefulness. In fact, 
phenytoin is useful for over fifty symptoms and disorders. These consist of 
the following: 
Thought, mood and behaviour disorders:  
• Psychosis;  
• Violent behaviour;  
• Alcoholism and drug addiction;  
• Sleep disorders;  
• Enuresis;  
• Anorexia, bulimia and binge Eating.  
Cardiovascular disorders:  
• Q-T interval syndrome;  
• Torsade de Pointes;  
• Tricyclic antidepressant overdose;  
• Angina pectoris;  
• Hypertension;  
• Atherosclerosis.  
Neuromuscular disorders:  
• Chorea minor (Sydenham's Horea);  
• Athetosis;  
• Dystrophic myotony;  
• Stiff-Man syndrome;  
• Restless legs syndrome;  
• Steroid myopathy;  
• Intractable Hiccups;  
• Respiratory myoclonus;  
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• Palatal myoclonus;  
• Hypocalcemia;  
• Tetanus.  
 
Treatment of pain in:  
• Trigeminal neuralgia;  
• Glossopharyngeal neuralgia;  
• Migraine;  
• Diabetic neuropathy;  
• Tabes dorsalis;  
• Postherpetic neuralgia.  
Healing in:  
• Periodontitis;  
• Ulcers;  
• Burns;  
• Epidermolysis bullosa;  
• Pachyonychia.  
Treatment of Other Disorders:  
• Diabetic diarrhoea;  
• Ulcerative colitis;  
• SIADH;  
• Transfusion reactions;  
• Head injuries and surgery;  
• Glaucomatous field loss.  
The Dreyfus Health Foundation, a not-for-profit organisation, began thirty 
years ago as the Dreyfus Medical Foundation. Jack Dreyfus, founder of the 
Dreyfus Funds and Corporation, started the foundation after treatment with 
 3
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phenytoin led to his recovery from endogenous depression. Finding that the 
uses of phenytoin were not widely known, he established the Dreyfus 
Medical Foundation sponsoring worldwide research and dissemination of 
information on this drug.  
Since 1970, three bibliographies summarising and analysing the medical 
literature on the uses of phenytoin have been distributed to physicians 
worldwide. These bibliographies were derived from the Foundation's library, 
which now contains over 16,000 papers. In 1980, Jack Dreyfus wrote a 
book, “A Remarkable Medicine Has Been Overlooked”, for the government, 
the medical profession and the public. A new edition of this narrative, plus 
the latest phenytoin bibliography “The Broad Range of Clinical Use of 
Phenytoin”, were sent free of charge to 508,000 physicians in the United 
States, in 1987. These books have also been translated into Italian, French, 
Russian, Chinese, Spanish and German (www.dhf-bg.org/phenen.html). 
Phenytoin is one of the oldest drugs used for the treatment of epilepsy. It has 
a very long history of effectiveness and safety. Because of this excellent 
track record, it is frequently the first drug used by many physicians to treat 
seizures. 
Over the past 5 years, a handful of new agents have been approved for use as 
antiseizure medications. Fosphenytoin is an example. It is a pro-drug form of 
phenytoin, and is rapidly cleaved by phosphatases in vivo to form phenytoin, 
as discussed further in section 1.1.2. 
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1.1.2. STRUCTURE-ACTIVITY RELATIONSHIP AND 
PHYSICOCHEMICAL PROPERTIES 
Phenytoin, 5,5-Diphenyl-2,4-imidazolidinedione; diphenylhydantoin (see 
Figure 1.1) exists as a white crystalline powder or granule. It is a diphenyl 
substituted hydantoin with much lower sedative properties than compounds 
with alkyl substituents at the 5 position and has a molecular formula 
C15H12N2O2. It is only minimally soluble in normal saline and must be 
dissolved in solution at a pH of 12.  
C
NH
N O
H
H5C6
H5C6
O
Phenytoin
 
Figure 1.1. Structure of Phenytoin 
The hydantoin [imidazoline-2,4-dione] ring containing two amide 
functionalities provide two chelatable electronegative atoms, N and O, in 
close proximity on the three faces of the heterocycle. This makes phenytoin 
a good candidate to interact with metallic ions (Milne, P. et al., 1999). 
 5
Fosphenytoin, a new drug, is a phosphorylated inactive version of phenytoin 
that is rapidly dephosphorylated by endogenous phosphatases to active 
phenytoin (Browne TR, et al., 1996) (see figure 1.2). It is quickly and 
completely converted to phenytoin and has no separate mechanism of 
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anticonvulsant activity. It is soluble in water and saline at pH 8.6 to 9.0. It is 
effective in animal models of Status Epilepticus (SE), and preliminary 
reports in humans are encouraging (Allen FH, et al, 1994). 
HN N
O
O
OPO3Na2
HN NH
O
O
H H
O
PO4
3-phosphatase
 
Figure 1.2.: Prodrug Fosphenytoin on the left going to Phenytoin in vivo 
1.1.3. SYNTHESIS 
Phenytoin can be synthesised in three steps from benzaldehyde. The first 
step in the synthesis is catalysed by thiamine (vitamin B1). The mechanism 
is fairly straightforward. The second step in the mechanism is a simple 
oxidation. The third step is complicated and involves an interesting 
rearrangement. This can be seen in Figure 1.3. 
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O
H
C
O
C
H
OH
Benzoin
HNO3
HOAc
C C
O O
O
NH2H2N
Urea
KOH/EtOH/H2O
OH
HN N
O
5,5-diphenylhydantoin
Benzaldehyde
Benzil
 
Figure 1.3.  Synthesis of 5,5-diphenylhydantoin (Mohrig, J.R. et al. 1997) 
1.1.4.    MODE OF ACTION AND RECEPTOR INTERACTIONS 
Phenytoin acts by promoting sodium efflux from neurons. The sodium ions 
tend to stabilize the threshold against hyperexcitability caused by excessive 
stimulation or environmental changes capable of reducing the sodium 
membrane gradient, depressing neuronal excitability.  
Phenytoin has major effects on several physiological systems. It alters Na+, 
K+ and Ca2+ conductances, concentrations of amino acids and the 
neurotransmitters norepinephrine, acetylcholine and γ-aminobutyric acid 
(GABA). Phenytoin blocks post titanic potentiation in spinal cord 
preparations, but the role of this effect in suppressing seizure spread is not 
yet defined. This effect is observed at therapeutically relevant 
concentrations. It is a use-dependent effect on Na+ conductance, arising from 
preferential binding to and prolongation of the inactivated state of the Na+ 
channel (Macdonald et al., 1993). 
 7
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Phenytoin may act via several different mechanisms, but the most studied is 
based on its interference with voltage-gated sodium channels (Macdonald 
RL & Kelly KM, 1993).  
In normal neurons, when the cell depolarises the action potential threshold, 
the voltage change transiently activates, or "opens," voltage gated Na+ 
channels at the axon hillock, which then propagates a single action potential 
down the axon. This allows cells to communicate with each other. The 
structure of the axon hillock and axon collaterals as well as the direction of 
signal propagation can be seen in Figure 1.4. The normal direction of 
information flow is from the axon terminal to the target neuron. As a result 
of this, the axon terminal is termed presynaptic and the target neuron is 
referred to as postsynaptic (Bear, et al., 2001). Figure 1.5. shows the typical 
synaptic transmission between the axon terminal of one neuron with the 
dendrite of the other. 
 
Figure 1.4. A diagram demonstrating the structure of the axon and cell 
body. The arrows indicate the direction and propagation of information flow 
(www.driesen.com/nervecell.jpg) 
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Figure 1.5. Synaptic transmission from the presynaptic neuron to the 
postsynaptic terminal (www.mhhe.com/biosci/ap/dynamichuman2/ 
content/gifs/0191s.gif)  
 
During prolonged depolarisation, for example during status epilepticus, the 
cell repetitively fires many action potentials and thus repetitively triggers 
other neurons. The same effect occurs in normal cells when they are 
artificially depolarised, resulting in sustained repetitive firing. Phenytoin 
prolongs inactivation of voltage gated Na+ channels and prevents sustained 
repetitive firing in vitro, but allows at least a single action potential to pass. 
Therefore, it allows "normal" signals to pass, but blocks passage of 
repetitive action potentials.  
There is also evidence that phenytoin prevents Ca2+ entry into neurons and 
thus may decrease excitability by this mechanism. Moreover, phenytoin, 
which decreases the excitability of neurons, has recently also been shown to 
block the rapid component of the delayed rectified potassium channel (IKr), 
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resulting in prolongation of the repolarisation phase of the action potential, 
in addition to its known blockade of sodium channels. 
1.1.5. PHARMACOKINETICS 
1.1.5.1. Absorption 
Absorption of phenytoin is highly dependent on the formulation of the 
dosage form. Absorption of phenytoin sodium from the gastrointestinal tract 
is nearly complete in most patients, though the time to peak may range from 
3 hours to 12 hours. Absorption from intramuscular injection is 
unpredictable and some drug precipitation in the muscle occurs. 
1.1.5.2.  Distribution 
Phenytoin is highly bound to plasma proteins. It appears certain that the total 
plasma level decreases when the fraction that is bound decreases, as in 
uremia or hypoalbuminemia, but correlation of free levels with clinical states 
remain uncertain. Drug concentration in the cerebrospinal fluid is 
proportionate to the free plasma level and phenytoin accumulates in and 
becomes bound to the endoplasmic reticulum of cells in brain, liver, muscle 
and fat. 
1.1.5.3.            Metabolism and Elimination 
Phenytoin is metabolised primarily by parahydroxylation to 5-(p-
hydroxyphenyl)-5-phenylhydantoin (HPPH), which is subsequently 
conjugated with glucuronic acid. The metabolites are clinically inactive and 
are excreted unchanged. At very low blood levels, phenytoin metabolism is 
proportionate to the rate at which the drug is presented to the liver, that is, 
first-order metabolism. However, as blood levels rise within the therapeutic 
range, the maximum capacity of the liver to metabolise phenytoin is 
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approached. Further increases in dose, even though relatively small, may 
produce very large changes in the drug’s concentration and patients can 
develop toxicity. The half-life of phenytoin varies from 12 hours to 36 
hours, with an average of 24 hours for most patients in the low- to mid-
therapeutic range. At low blood levels, it takes 5-7 days to reach steady state 
blood levels after every dosage change; at higher levels it may be 4-6 weeks 
before blood levels are stable. 
 
Phenytoin’s metabolism has been well studied. Four oxidative metabolites, 
49-HPPH, 39-HPPH, 39,49-diHPPH, and 39,49-dihydrodiol, are reported in 
humans (Figure 1.6.) (Maguire, 1988; Szabo et al., 1990).   
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4'-HPPH
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Figure 1.6. Proposed pathways of phenytoin metabolism in humans. 
(Maguire, 1988; Szabo et al., 1990) 
 11
Chapter 1                                                                                            Literature review 
It has been suggested that the anticonvulsant drug phenytoin is mainly 
metabolised to 49-HPPH by CYP2C9 (Bajpai et al., 1996). In addition 
Komatsu, T et al. (2000) discovered that CYP2C19, CYP2C9, and CYP3A4 
contributes significantly to 39,49-diHPPH formation from primary 
hydroxylated metabolites. Roles of these P450s vary among different human 
liver samples having compositions of various P450 enzymes. As a result, 
this might indicate potential contributions of multiple P450 enzymes in 
39,49-diHPPH formation. They also suggest that 49-HPPH formation and 
also other reactions (e.g., 39,49-diHPPH formation) can be involved in 
nonlinearity of phenytoin plasma concentrations or adverse phenytoin 
reactions in humans. 
 
1.1.6. THERAPEUTIC LEVELS AND DOSAGE 
The therapeutic level of phenytoin for most patients is between 10 to 20 
µg/ml. A loading dose can be given either orally or intravenously; the latter 
is the method of choice for convulsive status epilepticus. When oral therapy 
is initiated, it is common for adults to begin at a dosage of 300 mg/day 
regardless of body weight. While this may be accepted in some patients, it 
frequently yields steady state blood levels of 10 µg/ml, the minimum 
therapeutic level for most patients. If seizures continue, higher doses are 
usually necessary to achieve plasma levels in the upper therapeutic range. 
This is normally done with only small increments in dose. In children, a 
dosage of 5 mg/kg/day should be followed by readjustment after steady state 
plasma levels are obtained. 
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1.1.7. SIDE EFFECTS AND TOXICITY 
Nystagmus occurs early, as does loss of smooth extraocular pursuit 
movements, but neither is an indication for decreasing the dose. Diplopia 
and ataxia are the most common dose-related adverse effects requiring 
dosage adjustment; sedation occurs only at considerably higher levels. 
Gingival hyperplasia and hirutism occur to some degree in most patients; the 
latter can be especially unpleasant in females. Long-term chronic use is 
associated in some patients with the coarsening of facial features and mild 
peripheral neuropathy. Chronic use may also result in abnormalities of 
vitamin D metabolism, leading to osteomalacia. Low folate levels and 
megaloblastic anaemia have been reported, but clinical importance of this 
observation is unknown. Idiosyncratic reactions to phenytoin are relatively 
rare (Extra Pharmacopoeia, 1998) 
 
1.1.8.          INTERACTIONS OF PHENYTOIN 
 
Phenytoin is known to interact with a number of other drugs. These 
interactions are summarised in the Extra Pharmacopoeia (1998) and have 
been well-documented by Martin et al. (1971), Hartshorn (1972), Buchanan 
& Sholiton (1972). Kutt (1975) reports that a range of interactions may 
occur between antiepileptic drugs or between antiepileptic drugs and other 
therapeutic or chemical agents. As a result of these interactions, 
pharmacokinetic parameters such as solubility, absorption, metabolism, 
elimination and tissue distribution of the drug in question will be altered.  
 
From all the existing interactions, the specific interaction of phenytoin with 
metal ions will be dealt with. 
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1.1.8.1.    Interactions of phenytoin with metal ions 
 
Polyvalent cations such as aluminium, magnesium and calcium released 
from antacid preparations have been reported to interact with phenytoin, 
owing to a decreased in bioavailability of the drug (Garnett et al., 1979). 
Compounds can normally form chelates or complexes with these cations, 
and this may be the underlying cause of reduced drug absorption.  
 
Phenytoin forms a characteristic copper complex when treated with copper 
sulphate in pyridine solution. This reaction forms the basis for the B.P.C. 
identification test for this agent. In addition, studies carried out by Glazko 
and Chang (1972) reported the following: 
 
• A copper chelate is formed by adding CuCl2 to a solution of phenytoin 
dissolved in 0.1 M ammonium hydroxide and shaking continuously 
for 1 hour. 
• Phenytoin also appeared to form a complex with cobalt salts. 
• There was no indication of chelate formation with calcium, 
magnesium or ferrous salts. 
 
Furthermore, it was important to note that this formation took place in 
ammonia solution, which has a much higher pH as compared to the 
physiological pH of 7.4. 
 
Another study showed that zinc [Zn (II)] demonstrates affinity for each 
heteroatom (O and N) in phenytoin and that the Zn (II) cation coordinates 
with two phenytoin molecules at these respective sites. This suggests that 
phenytoin should be an excellent ligand for Zn (II) complexation (Milne, P. 
et al., 1999).  
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1.1.9.  TERATOGENICITY 
 
The Foetal Hydantoin Syndrome (FHS) consists of craniofacial defects and 
any two of the following: pre/postnatal growth deficiency, limb defects, 
major malformations, and mental deficiency. Available data suggest a 
prevalence of FHS of 10-30% in infants of women ingesting 100-800 mg/kg 
of phenytoin during the first trimester or beyond. 
 
Phenytoin produces multiple behavioural dysfunctions in rat offspring at 
subteratogenic and non-growth retarding doses. These behaviourally 
teratogenic doses produce maternal serum phenytoin concentrations in rats 
comparable to those found in humans. The dysfunctions in rats are dose-
dependent and exposure-period-dependent, but independent of nutritional 
habits. Effects include vestibular dysfunction, hyperactivity and deficits in 
learning and memory (Adams, J., et al., 1990) 
 
Azarbayjani, F., et al. (2002) found evidence that drug-induced embryonic 
arrhythmia initiates phenytoin teratogenicity. The arrhythmia, which links to 
the potential of phenytoin to inhibit a specific potassium channel (IKr), may 
result in episodes of embryonic ischaemia and generation of reactive oxygen 
species (ROS) at reperfusion. Danielsson BR, et al. (2001), also reported the 
same findings.  
 
Another important mechanism of teratogenicity of PHT involves the 
production of free radical reactive intermediary metabolite that lead to ROS 
formation, including hydroxyl radicals. In addition, ROS-initiated oxidation 
of DNA, proteins, glutathione (GSH), lipids and embryotoxicity have been 
shown to occur with phenytoin (Wells, P.G. et al., 1997).  
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According to Miranda AF et al. (1994), the depletion of GSH due to its 
oxidation by the toxic reactive free radical intermediate also contributes to 
the teratogenicity, as the latter plays a critical role in detoxifying a phenytoin 
free radical or subsequent activated oxygen species, thereby reducing 
covalent binding, lipid peroxidation, and oxidative stress that may initiate 
embryotoxicity or death. 
 
1.1.10.  PHARMACOLOGICAL NEUROPROTECTION 
BY PHENYTOIN 
Phenytoin is discussed here as a cerebroprotective premedication largely 
because it is cerebroprotective when given before global cerebral ischaemia 
but not when administered after the insult. It is a medication prescribed to 
patients dying from malignancies such as brain metastasis or primary brain 
tumour, HIV or other diseases, all of which involve the CNS.  
 
It is not generally recommended that phenytoin be used as a primary 
cerebroprotective drug except when administered IV during the agonal 
period because of its unfavourable adverse reaction profile that many 
patients suffer from.  
 
1.1.10.1.  In vivo evidence  
Voltage-dependent sodium channels have long been recognized targets for 
anti-arrhythmic and local anaesthetic drugs. Since the mid-1980s, Na+ 
channels have become widely accepted as the primary target of 
anticonvulsants with pharmacological profiles similar to phenytoin, 
carbamazepine, and lamotrigine. Results from animal models and a few 
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preliminary clinical trials suggest that this class of drugs may also offer 
significant potential for reducing the neuronal damage caused by ischaemia, 
stroke, head trauma, and perhaps certain neurodegenerative diseases. Studies 
using site-directed mutations of Na+ channels with electrophysiology have 
provided extensive insight into both the physiology and the interaction of 
drug molecules with ion channels. 
In a rabbit model of spinal cord ischaemia, retrograde perfusion with the 
sodium channel antagonist, phenytoin, is reported to be safe and provides 
significant protection during prolonged spinal cord ischaemia (Gangemi, J.J. 
et al., 2000) 
In 1990, Boxer PA et al. showed that phenytoin, which is not a glutamate 
antagonist, reduces the infarct volume in the brain by 45% at 28 mg/kg. A 
single dose of phenytoin (28 mg/kg) administered 30 minutes after hypoxia, 
was neuroprotective, but delaying drug administration for more than 2 hours 
was ineffective. The neuroprotective activity of phenytoin suggests that this 
may be related to the common anticonvulsant action due to sodium channel 
blockade, thus reducing the hyperexcitablility of neuronal membranes. 
Without question, the blockade of the excitatory response by phenytoin is 
due to its non-NMDA rather than NMDA glutamate receptor antagonistic 
effect. This is in agreement with Kawano et al. (1994).  
Moreover it is also suggested that non-NMDA glutamate receptor blockade 
results in considerable enhancement of the efficacy of antiepileptic drugs 
(Zarnowski et al., 1993). As a result this might be an important feature in the 
anticonvulsant profile of phenytoin and might be contributing towards 
neuronal protection in the hippocampal area where there is a great number of 
glutaminergic neurons.  
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Vartanian MG et al. (1996) used a model of hypoxia-ischaemia with 
neonatal rats where they showed that pre-treatment with phenytoin is 
neuroprotective at a plasma phenytoin concentration of approximately 12 
µg/ml. Phenytoin is also reported to be able to reduce lipid peroxide levels 
significantly in the rat brain, when given orally at a dose of 20 mg/kg as 
compared to a control group treated only with kainic acid (KA), an 
excitotoxic agent (Hsieh, C.L., et al., 2001).  
In the next section the aetiology via which damage can occur in neuronal 
cells by various excitatory amino acids is discussed. 
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1.2.          EXCITOTOXICITY 
 
1.2.1.  INTRODUCTION 
 
Glutamate though recognised as a beneficial excitatory neurotransmitter, 
also has the potential to be neurotoxic. Glutamate being an excitotoxin was 
recognised largely due to the work of Olney and his colleagues (1971 & 
1974) who demonstrated an association between the excitatory properties of 
various glutamate analogues, and their ability to produce neurotoxic damage 
at elevated concentrations in the brain (Meldrum, B. & Garthwaite, J. 1990).  
 
Excitotoxicity as described by Olney (Olney, J.W. 1995) refers to the 
contradictory property, shown by glutamate and certain particular EAA 
analogues, of causing severe degeneration to neuronal cells, by excessive 
stimulation of postsynaptic EAA ionotropic receptors through which 
glutamate functions as a transmitter.  
 
Agonists acting at the N-methyl-D-aspartate (NMDA) and KA receptors are 
among the most potent agents able to produce a combination of neuronal 
excitation resulting in neurodegeneration. In most cases the factors that are 
believed to start the neurodegenerative process is the accumulation of 
intracellular Ca2+. Agonists acting at the NMDA receptor induce increases in 
Ca2+ by activating ionic channels through which Na+, K+ and Ca2+ can enter 
the cell (Stone, T.W. 1993). KA receptor agonists cause an increase in Ca2+ 
by triggering the release of Ca2+ from intracellular stores.  
 
It is also possible that under certain pathological conditions such as hypoxia, 
hypoglycemia, seizure and epilepsy (MacDonald, J.F. & Nowak, L.M. 
1990), the transport system, namely these ionic channels mentioned above, 
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can be caused to operate in reverse. This results in the release of glutamate 
into the synaptic cleft. High synaptic glutamate concentrations can prove 
toxic to neurons. This is because glutamate toxicity is thought to be 
mediated by an increase in intracellular Ca2+ as the Ca2+ channel blocker 
nifedipine is able to prevent damage to cultured neurons treated with 
quinolinic acid (QUIN) and other excitotoxins having similar actions like 
glutamate (Weiss, J.H., et al. 1990). 
 
1.2.2.  NMDA RECEPTORS 
 
The NMDA receptor has a very complex molecular structure, containing 
binding sites for both glycine and glutamate (Jansen, K.L.R., et al. 1989). 
Both the glycine and glutamate sites must be occupied for activation to 
occur (Andjus, P.R., et al. 1996), and so they are referred to as “co-agonists” 
of the NMDA receptor (Blandini, F., et al. 1996). As discussed above, the 
NMDA receptors play a critical role in excitotoxicity and are classified as 
ionotropic glutamate receptors. Furthermore, the complex molecular entity 
has a number of distinct recognition sites for endogenous and exogenous 
ligands, each with discrete binding domains (Cooper, et al., 1996). In 
addition the NMDA receptor contains six pharmacologically distinct sites 
through which compounds can alter the activity of this receptor. The 
structure of the NMDA receptor is shown in Figure 1.7. 
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Figure 1.7. Diagrammatic representation of the NMDA receptor and sites of 
action of different agents on the receptor (Cooper, et al., 1996) 
 
Activation of the NMDA receptor is modulated by polyamines, such as 
spermine and spermidine (Williams, K., et al. 1991). Although the 
polyamine site need not be occupied for receptor activation, the presence of 
polyamines increases the ability of glutamate and glycine to open the 
NMDA-receptor ion channel (Yeneda, Y., et al. 1991). One of the most 
important factors of the NMDA receptor is the voltage-dependent blockade 
of the receptor ion channel by Mg2+ (Mayer, M.L., et al. 1984). At resting 
potential (about -70mV), normal extracellular concentrations of Mg2+ block 
the NMDA-receptor ion channel and prevent current flow, even when the 
glutamate and glycine sites are occupied. However, because the Mg2+ 
blockade is voltage-dependent, the degree of Mg2+ block is reduced as a 
neuron becomes depolarised (Dodd, P.R., et al. 1994) allowing more 
movement of ions. The NMDA receptor is ionotropic, permitting an 
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intracellular influx of Ca2+, as well as an exchange of Na+ and K+ across the 
cell membrane (Tilson, H.A. et al., 1995). Ca2+ permeability of the NMDA 
receptor is important as the increase in Ca2+ concentration activates a number 
of cellular and secondary messenger systems, and contributes to the 
initiation of long-term potentiation (Mayer, M.L. et al. 1990 & Madison, 
D.V. et al., 1991). Extracellular Zn2+ appears to act as an inhibitory 
modulator of channel function at a site near the “mouth” of the ion channel 
(Tilson, H.A. et al. 1995).  
 
A variety of competitive and non-competitive inhibitors exist for the NMDA 
receptor. Among the more common competitive inhibitors are 2-amino-5-
phosphonovalerate (AP5) which competes directly with glutamate for the 
binding site (Tilson, H.A. et al. 1995), while the non-competitive inhibitors 
dibenzocyclohepteneimine (MK-801), phencyclidine (PCP) and remacemide 
act within the ion channels to block current flow (Greenamyre, J.T. et al. 
1994, Tilson, H.A et al. 1995). High concentrations of the NMDA receptors 
are found in the cerebral cortex and CA1 regions of the hippocampus 
(Monaghan, D.T. et al. 1986). 
 
1.2.3.  MECHANISM OF EXCITOTOXICITY 
Normally glutamate, being a neurotransmitter, acts as a chemical signal 
between two neurons. The release of this neurotransmitter triggers the short-
lived opening of receptor-coupled channels, which allows ions to pass 
through the cell’s biological membrane [Poeggeler, B., et al. 1993]. High 
levels of glutamate, however, cause these channels to remain open for 
extended periods of time allowing an unusual, prolonged and finally fatal 
influx of ions into the neuronal cells. There are two principle processes in 
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which excitatory amino acids induce neurotoxicity that can result in loss of 
membrane integrity and cell death (Meldrum, B. et al. 1990). 
 
The first process, termed the acute process, involves the rapid swelling of 
neurons. This usually follows the excessive depolarisation, ion influx and 
water entry into the neurons. The second phase is slower. It is a delayed 
neurotoxic process that occurs secondary to Ca2+ influx (Tilson, H.A. et al. 
1995). These two processes are discussed in more detail in the next section. 
 
1.2.3.1. Acute Toxicity 
 
Acute toxicity occurs following the rapid influx of mainly Na+ into the 
neuron. This causes passive Cl- and water entry into the cell via changes in 
osmotic potentials. This toxic process occurs within minutes and depends on 
the presence of extracellular Na+ and Cl- ions stores. It may be associated 
with abnormalities in membrane permeability and may lead to cell death via 
osmotic lysis. Under certain conditions, the neuron may be able to re-
establish osmotic pressure and hence stay alive. This process can be 
mimicked by depolarising agents such as veratridine, an agent which 
prevents the inactivation of voltage-dependent Na+ channels, opening them 
for long periods of time (Churchwell, K.B., et al.1996) or by increasing 
extracellular K+ concentrations.  
 
The process that takes place may be direct, by over-excitation of the 
neuronal cells resulting in a prolonged depolarisation and depletion of 
energy stores, or indirectly, for example by excessive Na+ ion influx 
resulting in Ca2+ build up via Na+ / Ca2+ exchange ion channels present 
within the cell membrane. 
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1.2.3.2.  Delayed Toxicity 
 
Delayed toxicity results from a Ca2+ influx which is mediated by the NMDA 
receptor. The increase in intracellular Ca2+ concentration can lead to a 
cascade of pathophysiological events. These can promote oxidative stress 
leading to neuronal damage and subsequent cell death (Coyle, J.T. et al. 
1993). The cascade of events that results from the increase in intracellular 
Ca2+ and leads to neurotoxicity can be seen in Figure 1.7. 
 
 
 
Figure 1.8. Schematic representation of the NMDA-receptor mediated 
processes (Kaul M & Lipton SA, 2000) 
 
In the majority of instances Ca2+ influx does not actively initiate cell death, 
but rather activates a number of enzymatic and metabolic processes that set 
in motion a process that can prove to be neurotoxic. To a certain extent, 
 24
Chapter 1                                                                                            Literature review 
these alterations can be reversible. This can be deduced from the fact that 
glutamate receptor antagonists do confer an extent of neuroprotection 
several hours after an excitotoxic insult (Leigh, P.N. et al. 1996). 
 
Nevertheless, in most cases, once the process has been initiated, neuronal 
cell death results. Among the processes triggered by increased Ca2+ 
concentrations, is the activation of proteases such as calpain-1. These 
enzymes can degrade major neuronal structural proteins, and induce 
cytoskeletal breakdown (Seubert, P et al. 1988). Calpain also cleaves 
xanthine dehydrogenase to convert it to xanthine oxidase (Meldrum, B. & 
Garthwaite, J. 1990, Atlante, A et al.1997). This enzyme is responsible for 
the conversion of hypoxanthine to uric acid and also the production of 
superoxide anions in the process (Coyle, J.T., et al. 1993, Wie, M.B., et 
al.1997).  
 
Ca2+ can also bind to calmodulin to form Ca2+-calmodulin complexes. The 
role of this complex in mammalian cells is to modulate the activity of a large 
number of enzymes (Ross, E.M. et al. 1980). Among the processes activated 
are Ca2+-calmodulin-linked protein kinases, which disrupt the cytoskeleton 
(Wang, Y.T et al. 1996) and can cause mitochondrial dysfunction. Ca2+-
calmodulin complexes can also activate nitric oxide synthase (NOS) 
(Scatton, B. 1994), which produces nitric oxide (NO), a toxin that has been 
implicated in numerous neurological diseases (Dodd, P.R, et al. 1992).  
 
Further more, free radical production has been linked to a loss of cellular 
Ca2+ homeostasis. Dykens (1994) reported that isolated cerebral and 
cerebellar mitochondria produce free radicals when exposed to elevated 
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Ca2+. Mitochondria play an important role in the removal of Ca2+ from cells 
after a glutamate insult (White, R.J. et al. 1997, Khodorov, B., et al.1996).  
 
Ca2+ is sequestered to the mitochondrial matrix, (Budd, S.L. et al. 1996) 
driven by the proton electron chemical gradient generated by the electron 
transport chain (Ankarcrona, M., et al. 1996). The reduction in the 
electrochemical gradient caused by the Ca2+ influx decreases ATP synthesis 
(Khodorov, B., et al.1996), at a time when there is enormous demand for 
ATP by the plasma membrane Ca2+ pump, and indirectly by the Na+/Ca2+ 
exchanger (Schinder, A.F., et al. 1996). Mitochondrial Ca2+ accumulation 
and the subsequent permeability transition may therefore be a critical early 
event specific to the NMDA receptor mediated excitotoxic cascade (White, 
R.J. et al. 1996). 
 
1.3.   QUINOLINIC ACID 
1.3.1. INTRODUCTION 
 
Quinolinic acid (QUIN) is a naturally produced metabolite of tryptophan 
metabolism. QUIN is a structural analogue of NMDA and also a precursor 
for NAD (Foster, A.C et al. 1983, Heyes, M.P. et al. 1997, Heyes, M.P., et 
al. 1996, Wolfensberger, M., et al. 1984). QUIN has been shown to be 
present in normal post-mortem human brains at levels similar to those of 
other species (Wolfensberger, M., et al. 1984) and with concentrations not 
varying greatly among the different regions of the brain. Heyes and 
Morrison (1997) demonstrated that the brain naturally synthesises QUIN, 
and that the rate of QUIN formation increases in conditions of brain and 
systemic immune activation. QUIN concentrations have also been shown to 
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increase during the natural ageing process in rats (Moroni, F., et al.  1984). 
Foster et al., 1984 showed that there is no active uptake of QUIN from the 
extracellular space, nor is there extracellular metabolism of QUIN. It is 
therefore unlikely that QUIN is a neurotransmitter in the classical sense. 
QUIN is however a selective agonist for the NMDA category of receptors.  
 
Stone and Perkins (1981) demonstrated that QUIN is about 25% as active as 
NMDA, and approximately as active as glutamate and aspartate in 
stimulating NMDA receptors. Moreover, the latter compounds have a rapid, 
high-affinity uptake system for their removal from the synapse, while QUIN 
does not. Because QUIN is not removed from the synaptic cleft, QUIN will 
continue stimulating the NMDA receptor. As a result, this makes it a very 
potent neurotoxin. 
 
The role of QUIN in physiology is not yet very clear, while in pathology an 
abnormal accumulation of QUIN in the brain has been proposed as one of 
the causes of convulsions (Lapin, 1981), Huntington’s disease (Schwarcz et 
al. 1986), hepatic encephalopathy (Moroni et al.1986b, c) and recently also 
acquired immuno deficiency syndrome (AIDS)-related neurological 
disorders (Brown, 1990). 
 
1.3.2.     SYNTHESIS AND METABOLISM OF QUINOLINIC 
ACID 
 
QUIN is synthesised according to the kynurenine pathway shown in Figure 
1.9. The kynurenine pathway starts with oxidative cleavage of the amino 
acid, tryptophan by the haem dependent enzyme, tryptophan-2,3-
dioxygenase. The product of this cleavage is N-formylkynurenine, which is 
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hydrolysed by a formamidase enzyme to give kynurenine, the amino acid 
responsible for this particular pathway’s name. Kynurenine is situated at a 
branching point and metabolism can result in a number of secondary 
metabolites. Kynurenine could either be converted to anthranilic acid, 
utilised in the biosynthesis of aromatic amino acids; or transamination 
catalysed by kynurenine amino transferase yielding kynurenate or 
sometimes be employed in the biosynthesis of quinolines. However the third 
possibility and the most important route for the synthesis of QUIN, is the 
oxidation of the benzene ring catalysed by kynurenine-3-hydroxylase. At 
this point, kynureninase fragments the 3-hydroxykynurenine to give 3-
hydroxyanthranilic acid and alanine (Botting, 1995). 
 
The synthetic enzyme for QUIN in the kynurenine pathway, 3-
hydroxyanthranilic acid oxygenase (3-HAO), catalyses the conversion of 3-
hydroxyanthranilic acid to an unstable intermediate, α-amino-β-
carboxymuconic semialdehyde also referred to as 3-acroleyl-3-amino-
fumarate. This then spontaneously rearranges to form QUIN (Foster et al., 
1986). 3-hydroxyanthranilic acid oxygenase is an iron dependent enzyme 
requiring Fe2+ ions and sulfhydryl groups for its activity. It has become an 
important target for drug action as its inhibition provides the most direct 
method of reducing QUIN levels. 
 
QUIN is eventually catabolised to NAD (nicotinic acid dinucleotide) and 
carbon dioxide after being acted upon by quinolinate phosphoribosyl 
transferase (QPRTase). This enzyme has been identified in rat and human 
brain tissue (Foster, et al., 1985).  Magnesium ions are required for 
QPRTase activity and there is evidence that an active site containing a 
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cysteine residue is necessary for catalysis, while lysine and histidine residues 
are also essential (Botting, 1995). 
 
Usually, there exists a differential localization of the two enzymes, 3-HAO 
and QPRTase in the brain, with 3-HAO localised almost entirely in the 
soluble fraction of brain homogenate and QPRTase to the particulate 
component of P2 synaptosomal fractions (Stone, 1993). In view of this, 
QUIN must be synthesised in one category of glial cells and must exit those 
cells to be metabolised by QPRTase in a separate population of QPRT-
containing glial cells and neurons (Heron, P.M., 2001) 
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Figure 1.9. A schematic outline of the kynurenine pathway-yielding QUIN 
(Stone, 2000) 
 
1.3.3.             QUIN AND NEUROLOGICAL DISORDERS. 
 
QUIN is a known neurotoxin and has been implicated in several 
neurological disorders. There are numerous factors that contribute towards 
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QUIN toxicity. One of the factors is the involvement of the enzymes in the 
metabolic and synthetic pathway of this neurotoxic agent. Previous studies 
have shown that two of the enzymes namely 3-HAO and QPRTase even 
though they have almost similar Km values exhibit different kinetic profiles. 
The kinetics of 3-HAO was 80 times higher than that of QPRTase (Foster, et 
al., 1986). As a result, the production of QUIN occurs at a much faster rate 
within the CNS than the conversion to NAD. An imbalance in this 
equilibrium may play an important role towards the accumulation of the 
neurotoxin in the brain during certain neuro-pathophysiological diseases.  
 
Moreover, it has been reported that 3-HAO is primarily found in areas of the 
frontal cortex, striatum and hippocampus, which possess little detectable 
QPRTases (Stone, 1993). Thus QUIN could reach high enough 
concentrations to induce excitotoxic damage in these regions. Furthermore, 
if the damage occurs in the hippocampal area, this can influence memory 
processes resulting in a cognitive decline and memory loss resembling 
Alzheimer’s disease. Saito et al., 1992, reported that the concentration of 
QUIN in the hippocampus of gerbils is normally 65 nM and this 
concentration was found to increase to 1466 nM after 4 days of ischaemia. 
Given the fact that Fe2+ ions are released during neuronal damage and 
considering that the activity of 3-HAO may normally be restrained by 
factors such as availability of Fe2+ ions (Stone, 1993).  It is possible that this 
phenomenon might contribute towards the significant increase in levels of 
QUIN in the CNS during neurodegenerative diseases. 
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In addition, when radiolabelled QUIN was injected into the hippocampus, 
the radiolabelled compound was cleared from this CNS region with a half-
life of 22 minutes and all residual radioactivity recovered after 2 hours was 
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still due to QUIN. This region thus does not appear to possess mechanisms 
neither for the rapid removal of QUIN nor for its metabolic degradation in 
the extracellular space by QPRTase (Foster, et al., 1984). Consequently this 
lack of uptake systems and extracellular metabolism within these 
hippocampal neurons will promote the ability of QUIN to induce excitotoxic 
damage to these cells. 
 
1.3.4.         MECHANISMS BY WHICH QUIN INDUCES      
NEUROTOXICITY. 
 
QUIN is an endogenous excitotoxic L-tryptophan and kynurenine pathway 
metabolite. It can function as a neurotoxin by acting as  an agonist of the N-
methyl-D-aspartate (NMDA) receptors (Stone, T.W. et al. 1981). In 
addition, neurotoxicity caused by this agent can also involve transcription 
factors, apoptosis, cytoskeletal disruption and lipid peroxidation. NMDA 
receptor agonists such as QUIN, glutamate and NMDA cause neuronal 
excitation. The chain of events culminating from this excitation and 
subsequent neurodegeneration can be referred to as neurotoxicity. 
 
QUIN is able to produce neurotoxicity only in the presence of afferent fibres 
to the area of investigation. Thus the latter is ineffective as a neurotoxin in 
the hippocampus following transection of the perforant path as reported by 
Keiloff, et al. (1992). This suggests that presynaptic terminals may be an 
essential feature of the neurotoxic activity of QUIN. This further means that 
either QUIN may promote the release of secondary neurotoxic agents from 
nerve terminals, or that the postsynaptic effects of QUIN depend on the 
permissive or enhancing effects of factors released from presynaptic 
terminals (Stone, 1993).  
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Direct intra-hippocampal QUIN acid injections are reported not to be able to 
induce the disruption of DNA molecules characteristic of apoptosis 
(Ignatowicz, et al., 1991). This suggests that QUIN is not likely to be 
involved in the initiation of such above-mentioned process. 
 
Stone, 1993, has also suggested that the initial disruption of the cytoskeleton 
by QUIN through changes in the protein, fodrin, a major component of the 
neuronal cytoskeleton in the CNS, leads to the efflux of amino acids 
resulting in cell death. 
 
Moreover, QUIN is able to increase lipid peroxidation in rat brain 
homogenate (Rios & Santamaria, 1991) and since lipid peroxidation is the 
damage related to free radical formation, this may suggest that this 
neurotoxic agent might also mediate its toxicity partly via this free radical 
mechanism. 
 
1.3.5.         NEUROPROTECTION AGAINST QUIN 
 
Lees, 1987 reported that several agents, namely 2AP5, MK-801 and 
ketamine, all antagonists at the NMDA receptor, are protective against 
QUIN-induced toxicity. Certain metallic ions such as zinc and even 
systemically administered magnesium are effective (Wolf, et al., 1990), 
however this may be related to their general depressant effect on neuronal 
excitability, or on the release of essential presynaptic factors, than to 
selective suppression of NMDA receptor function (Stone, 1993). 
 
Moreover with respect to QUIN toxicity, there have been few reports of 
agents that can be applied systemically to confer protection. Most 
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antagonists mentioned above have very little activity in this respect, except 
MK-801 and more recently, mermantine. The latter, when administered 
orally can be protective against QUIN (Keiloff & Wolf, 1992). Moreover 
newer antioxidants compounds such as melatonin have also been proven 
effective in vitro against QUIN neurodegeneration (Southgate et al., 1999) 
but their clinical uses are still limited.  
 
1.4.  OXIDATIVE STRESS AND FREE RADICALS 
 
1.4.1. INTRODUCTION 
 
Almost all of the processes described in the previous section lead either 
directly or indirectly to the elevated production of free radicals. The 
production of oxygen free radicals is a natural consequence of aerobic 
metabolism, with these molecules constantly being generated in the body by 
normal metabolic processes (Ames, B.N., et al. 1993). By definition, 
oxyradicals are molecular species capable of independent existence and 
contain one or more unpaired electrons (Halliwell, B. 1992). The loss of an 
electron leaves a molecule more reactive than its paired counterpart. If two 
radicals react, both radicals are quenched, while if a radical reacts with a 
nonradical, another free radical must be produced. This characteristic allows 
free radicals to participate in chain reactions, which may be thousands of 
events long (McCord, J.M. 1985). This chain of reaction is discussed further 
in section 1.4.5. 
 
Although there are a variety of free radicals produced by molecules, those 
that are produced from molecular oxygen have received the most 
investigative interest (Reiter, R.J., et al. 1995). The oxygen species that are 
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typically linked to oxidative stress are superoxide anion radical (O2-.), the 
hydroxyl radical (.OH.) (Cheesman, K.H. et al. 1993), hydrogen peroxide 
(H2O2) (Hoyt, K.R., et al. 1997), nitric oxide (NO) and peroxynitrite 
(ONOO.). The collective term for these chemicals is “reactive oxygen 
species” (ROS), but not all of these species are particularly active in aqueous 
biological solutions (Dawson, V.L. et al. 1996). 
 
1.4.2  FREE RADICALS 
1.4.2.1. The Superoxide Radical 
The free radical O2-. can be generated by multiple enzymatic and non-
enzymatic pathways and is often found at the initial stages of the oxidative 
stress cascade. Mitochondria are one of the main producers of other O2-. 
(McCord, J.M. 1985). In addition other organelles such as chloroplasts and 
the endoplasmic reticulum also produce these reactive species where 
electron transport chains occur too (Halliwell and Gutteridge, 1990). During 
the production of ATP via the electron transport chain (Dawson, V.L. and 
Dawson, T.M. 1996), the oxygen molecule can be reduced to O2-.. The body 
protects itself against this by kinetically restricting these reactions. 
Nevertheless, 1 to 3% of high-energy electrons “escape” in close proximity 
to oxygen resulting in the formation of O2-. (Coyle, J.T. & Puttfarcken, P. 
1993). As mentioned previously, cumulatively this minute amount of O2-. 
leakage leads to the production of up to 2 kg of O2-. during the year. The O2-. 
radicals can also be generated chemically by auto-oxidative reactions with 
catecholamines, tetrahydrofolates and reduced flavins. This can lead to a 
free radical chain reaction as the production of O2-. leads to the autocatalysis 
of further O2-. species. 
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Most of the O2-. generated in a cell is converted to H2O2 by superoxide 
dismutase (SOD)-catalysed dismutation (DiFiglia, M. 1990, Halliwell, B. 
1992). This conversion can also occur by non-enzymatic processes. The 
H2O2 that results from dismutation is then metabolised by either catalases, or 
one of the peroxidases namely glutathione peroxidases to produce water and 
oxygen (Mathews, K. & Van Holde, K.E. 1990). Hence H2O2 is not itself a 
free radical and has limited reactivity. However it can cross biological 
membranes, which superoxide can only do at a much slower rate. The 
toxicity related to H2O2 to cells varies. This can be attributed to the activity 
of H2O2-removing enzymes and presence of metallic ions such as Fe2+. Fe2+ 
can catalyse the conversion of H2O2 into more highly reactive radicals by the 
Fenton reaction. One such radical is the hyroxyl radical .OH. (Halliwell & 
Gutteridge, 1990). 
 
1.4.2.2.  The Hydroxyl Radical 
The .OH radical is probably the most reactive of the ROS species 
(Poeggeler, B., et al.1993, Dawson, V.L. & Dawson, T.M. 1996). This is 
because it will react with almost all molecules in living cells (Fridovich, I. 
1986). It is so reactive that no enzyme systems utilising it as a substrate exist 
(Bird, E.D. & Iversen, L.L. 1974). The estimated diffusion distance is 0.3 
nm or one-hundredth the diameter of a typical protein (Beckman, J.S. 1994). 
This implies that reaction of the radical followed by damage will occur 
where the .OH is formed. The .OH radical has been implicated in damage to 
macromolecules such as proteins, carbohydrates, DNA and lipids (Reiter, 
R.J., et al. 1995). Most of the hydroxyl radicals generated in biological 
systems are formed when transition metals (Oliver, C.N., et al. 1990) or 
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biologically active chelators, such as porphyrins and flavins are present 
simultaneously with an oxidant, such as hydrogen peroxide (Poeggeler, B., 
et al.1993). The breakdown of hydrogen peroxide is described by the Fenton 
reaction in detail in section 1.4.4. (Coyle, J.T.et al. 1993, Poeggeler, B, et 
al.1993). 
1.4.3.  DEFENCE MECHANISMS AGAINST ROS 
NEUROTOXICITY 
The body has many defence mechanisms to counteract oxidative stress 
(Machlin, L.J. et al. 1987). This can occur by enzymatic and non-enzymatic 
processes (see Table 1.1). These enzyme systems are normally distributed 
evenly inside cells (McCord, J.M. 1985), and under normal circumstances 
these defence mechanisms can deal with the production of ROS in the 
neuron. It is only when there is either an increase in oxygen radical 
production, or cellular ROS defence systems are compromised, that 
neurotoxicity occurs (DiFiglia, M. 1990).  
 
Table 1.1: Cellular defence / anti-oxidant mechanisms accessible to neurons 
to protect against ROS species (Machlin, L.J. et al. 1987) 
 
Enzymatic Non-Enzymatic 
                                                         
Cu / Zn-Superoxide Dismutase        
Mn - Superoxide Dismutase             
Glutathione Peroxidase                    
Glutathione-S-Transferase 
Glutathione Reductase 
Catalase 
 
  
Ascorbic Acid (Vitamin C) 
Tocopherol (Vitamin E) 
Glutathione 
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The functioning of these enzymes depends to a large extent on scavenging of 
the reactive chemical entities. The non enzymatic-pathway mostly consists 
of agents that have good ability to accept electrons. These agents are found 
predominantly in the reduced state rather than their oxidised form and this 
optimises their electrophillic properties (Dawson & Dawson, 1996) 
 
1.4.3.1 Chemical reactions of the defence mechanisms 
 
2O2. + 2H+   Æ  H2O2 + O2   (SOD, Enzymatic)                            [1] 
2H2O2 Æ  O2  +  2H2O     (Catalase, Enzymatic)                          [2] 
2GSH + H2O2  Æ  GSSG  +  2H2O     (Enzymatic)                       [3] 
GSSG + NADPH + H+ Æ 2GSH + NADP+    (Enzymatic)           [4] 
Reaction [1] involves the breakdown of O2.  by SOD to produce non-toxic 
hydrogen peroxide and oxygen. This reaction can happen at the 
mitochondrial matrix and in the cytoplasm. This is due to the fact that two 
distinct SODs have been isolated in these regions in eukaryotes. 
 
The route of H2O2 decomposition is concentration dependent. At low 
concentrations of H2O2, reaction [3] is favoured and glutathione peroxidase 
catalyses the conversion of hydrogen peroxide to water by the oxidation of 
glutathione. The reduced form of glutathione is regenerated in reaction [4] 
by the action of glutathione reductase. However, at high concentrations, 
H2O2  is removed by the enzyme catalase via reaction [2], (Fahn & Cohen, 
1992) 
 
 
 37
Chapter 1                                                                                            Literature review 
1.4.4. THE INVOLVEMENT OF METAL IONS 
 
As reported by Halliwell and Gutteridge, (1989), ions of transition metals 
such as copper and iron are involved in free radical generation. In the case of 
iron, only the unbound free iron is able to stimulate free radical generation. 
Iron in human plasma is normally bound to protein carriers such as 
transferrin. Free radicals, more precisely hydroxyl radicals, are generated via 
the Fenton reaction [5] in the presence of iron (II) as shown below. 
 
H2O2 + Fe2+ Æ  OH- + OH. + Fe3+                                [5] 
Fe3+ + O2. Æ Fe2+ + O2                                                           [6] 
O2. + H2O2 Æ O2  + OH- + OH.                               [7] 
 
The Fenton reaction can be further potentiated by the regeneration of the 
toxic iron (II) from the reaction of iron (III) generated in reaction [5] and 
superoxide anions as seen in reaction [6]. Consequently, reaction [5] and [6] 
give rise to the net reaction equation [7], the iron-catalysed Haber-Weiss 
type of reaction. 
 
In summary, these reactive species produced have the capacity to cause 
severe damage to the neurons. In addition cells have the ability to reduce 
their toxicity by preventing their formation, metabolising hydrogen peroxide 
as stated previously and finally not allowing iron to take part in the reaction 
by keeping it in inactive sites or bound to carrier proteins (Fahn & Cohen, 
1992). 
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1.4.4.1.  Implication of iron in neurological disorders 
 
There is considerable evidence to demonstrate that endogenous iron stores 
are partially available for participating in peroxidative damage in tissue 
(Halliwell & Gutteridge, 1986). Iron has been linked to the oxidative stress 
hypothesis for example, in Parkinson’s disease. In this disease the substantia 
nigra is the main region of the brain where cell damage occurs. Moreover, 
the substantia nigra is rich in dopamine and iron (Youdim, 1988a). This is 
further discussed in section 1.4.6.2. 
 
1.4.5. LIPID PEROXIDATION 
Most of our current information concerning biological membranes comes 
from the fluid mosaic model, proposed by Singer and Nicholson in 1972. 
They proposed that a membrane consists of a lipid bi-layer, interspersed 
with proteins and carbohydrates. The membrane is a dynamic system, and 
the composition depends on where in the cell it is located. Membranes 
function to compartmentalise the cell, as well as providing a surface from 
which ATP can be produced, receptors can bind, and where the transport of 
substances can be controlled. The structure and integrity of membranes is 
therefore essential for the successful functioning of the cell. 
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Lipid peroxidation is a process whereby membranes are destroyed by 
oxidative attack from ROS. Of all the major classes of biomolecules 
attacked by ROS, membrane lipids are probably the most susceptible to 
oxidative attack because of the high levels of polyunsaturated fatty acids 
(PUFA) present in these macromolecules. Lipid peroxidation is also 
extremely damaging because self-perpetuating chain reactions are caused by 
ROS attack.  
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Table 1.2. illustrates the three features, which characterise the lipid 
peroxidation process. During the initiation step (reaction 1) PUFA are 
attacked by ROS (In.), resulting in the removal of a hydrogen atom from the 
PUFA (RH) and the formation of a lipid-derived radical (R.). The 
propagation step (reaction 2) normally begins with the rapid addition of 
molecular oxygen to R., to form the lipid peroxyl radical (ROO.). This 
radical can attack other lipids, to generate a further lipid radical and a lipid 
hydroperoxide (ROOH). A self-perpetuating autocatalytic reaction then 
follows with reactions 2 and 3 undergoing a number of cycles (Krinsky, N.I. 
1992). The final step is a termination step, which results when two ROO. 
radicals react together to form a non-radical product (Burton, G.W. & 
Ingold, K.U. 1989). The removal of ROS by various antioxidant systems is 
therefore essential to limit lipid peroxidation in cells. 
 
Table 1.2. Chain sequence for free radical auto-oxidation. 
 
 
Initiations step            In.  +  RH     Æ    InH.   +   R.             Reaction 1 
 
 
Propagation                 R.    +   O2     Æ    ROO.                     Reaction 2 
Reactions 
                                     ROO. + RH   Æ   R.  +  ROOH           Reaction 3 
 
 
Termination               2 ROO.    Æ    Non-radical products  Reaction 4 
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1.4.6.   FREE RADICALS AND 
NEUROPATHOLOGICAL CONDITIONS 
 
1.4.6.1.  Free radicals and Ageing 
From the day an animal is born it begins to age. Ageing is therefore a natural 
phenomenon, and although the process cannot be stopped there are many 
physiological factors that can either advance or slow the ageing process. 
ROS are believed to be responsible for acceleration of the ageing process. 
These molecules affect the integrity of the macromolecules in the cell. 
Although most of the ROS produced are rapidly removed from the cell by 
the antioxidant defence system, there is a slow accumulation of damage that 
occurs during an animal’s life. It is estimated that 10000 oxidative hits occur 
on DNA in the human per day (Ames, B.N., et al., 1993). These damages are 
repaired by enzymes that excise the lesion, however there is a steady 
increase in the number of lesions as the animal ages. Viani et al (1991) 
compared young, adult and old rat brains. The group found that old brains 
were more susceptible to lipid peroxidation, demonstrating that peroxidation 
injury can have even more dramatic consequences when it takes place in the 
aged brain. 
 
The reason why the aged brain is more susceptible to ROS damage, is due to 
the fact that many of the neuroprotective pathways are no longer as effective 
as they are in younger animals. 
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1.4.6.2.   Free radicals in neurological disorders 
 
Ischaemia, cardiac arrest, thrombotic stroke and asphyxia all involve very 
different pathophysiologies though they all are thought to contribute to the 
neuronal degradation that occurs following cerebral ischaemia (Meldrum, B. 
& Garthwaite, J. 1990). Phillis et al (1994) found that while ischaemia 
causes an increase in glutamate release into the extracellular space, 
glutamate levels tend to undergo a further, unexpected rise during the initial 
30 to 40 minutes reperfusion. This could have resulted from the formation of 
toxic free radicals, including hydroxyl radicals (McIntosh, T.K., et al., 
1990). Following reperfusion there is also a burst of ROS production as 
xanthine oxidase metabolises hypoxanthine that has accumulated during the 
ischaemia (McCord, J.M. 1985). 
 
Parkinson’s disease is a chronic, progressive disorder of late life, which is 
characterized by rigidity, unintentional tremor and bradykinesia. Glutamate 
appears to play a very important role in the pathophysiology of Parkinson’s 
disease, as abnormal patterns of glutamatergic neurotransmission are 
important symptoms of Parkinson’s disease (Blandini, F., et al., 1996). The 
metabolism of dopamine by monoamine oxidase can yield 6-
hydroxydopamine, which is known to yield ROS (Cohen, G. & Spina, M.B. 
1989). Although proof that ROS stress actively causes the loss of 
monoaminergic neurons in Parkinson’s disease is lacking, there is 
considerable evidence in animals and humans to support the hypothesis 
(DiFiglia, M. 1990). Total iron is increased and ferritin is reduced in the 
substantia nigra pars compacta in patients with Parkinson’s disease. When 
this occurs, the transition metal is in a low molecular weight form, capable 
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of catalysing non-enzymatic oxidative reactions, especially the conversion of 
H2O2 to OH. (Simon, R.P., 1984). 
 
Alzheimer’s disease on the other hand involves selective and progressive 
degeneration of lower motor neurons in the spinal cord, and the upper motor 
neurons in the cerebral cortex. Symptoms normally become apparent in mid-
life (Coyle, J.T. & Puttfarcken, P., 1993). The disease is characterised by an 
abundance of senile plaques and neurofibrillary tangles in certain areas of 
the brain (Dodd, P.R., 1994). Amyloid β-protein has been implicated in 
neurotoxicity, where it is thought to induce the production of free radicals 
(Goodman, Y., et al. 1996) and disrupt calcium homeostasis (Mattson, M.P., 
et al., 1992). Mark et al. (1995) showed that amyloid β-peptides induce free 
radical production, which results in impairment of ion channels and calcium 
influx (Goodman, Y., et al. 1996). 
 
1.4.7. MOLECULAR TARGETS OF OXIDATIVE STRESS 
Damage resulting from oxidative stress does not always lead to the 
formation of lipid peroxides in damaged or injured neuronal cells. Damage 
to DNA and proteins are of equal or greater importance in vivo (Halliwell, 
1987). Further evidence suggests that this process is instrumental in a variety 
of normal and pathological processes, such as ageing, neutrophil function, 
rheumatoid arthritis and oxygen toxicity (Oliver, et al., 1990). 
 
1.4.8. NEUROPROTECTIVE STRATEGIES 
Much of the focus for neuroprotective strategies has been placed on specific 
targets elucidated through basic studies of neurotoxicity. It should be noted 
that each of the neuroprotective therapeutic targets identified in some way 
 43
Chapter 1                                                                                            Literature review 
contributes to the sparing of energy in nervous tissue (Obrenovitch & 
Urenjak, 1997). Thus, agents such as voltage dependent sodium and calcium 
channel blockers, glutamate receptor agonists, GABA and adenosine 
agonists all decrease membrane excitability and reduce the utilization of 
ATP for membrane repolarisation and calcium compartmentalization. 
Reduction of oxygen free radicals and nitric oxide may lower the utilization 
of ATP for membrane and macromolecular repair and may prevent the futile 
depletion of NAD and ATP (Azbill et al., 1997).  
Other therapeutic strategies such as hypothermia probably also work by 
reducing demands on cellular ATP levels. Future clinical neuroprotective 
strategies in traumatic brain and spinal cord injury may benefit by focusing 
on the maintenance of brain spinal cord energy levels through a combination 
of pharmacological approaches (Verma, A., 1999)  
 
1.4.8.1. Inhibition of Glutamate Release 
 
Many neuroprotective strategies for limiting CNS injury in recent years have 
focused on reducing the release of glutamate from presynaptic endings and 
preventing its actions at postsynaptic receptors. While excessive 
extracellular glutamate levels undoubtedly promote secondary brain injury 
following trauma (Liu et al., 1997), agents that block presynaptic sodium or 
calcium channels may potentially prevent the large increase in extracellular 
glutamate concentrations following brain injury. Several such agents 
including riluzole, lubelazole, BW619C89, phenytoin and fos-phenytoin are 
currently under investigation for this purpose. 
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1.4.8.2. Inhibition of Glutamate Receptors 
 
Several compounds that inhibit NMDA receptors non-competitively or 
competitively with respect to the glutamate-binding site have been 
developed for potential use as neuroprotective agents. Non-competitive 
NMDA antagonists like ketamine, phencyclidine (PCP), dizolcipine (MK-
801), dextrorphan and dextromethorphan bind to the phencyclidine 
recognition site in the NMDA-gated ion channel (Wong et al., 1986). 
Studies with dizolcipine and other NMDA receptor blockers indeed have 
demonstrated that such agents do improve functional outcome and 
histological morphology following experimental TBSI (Haghighi et al., 
1996; Rienert & Bullock, 1999).  
 
1.4.8.3.  Free Radical Scavengers 
 
Several potential agents exist for neuroprotective strategies aimed at 
reducing free radical formation in the acute setting following TBSI. These 
include superoxide dismutase, catalase, vitamin E, iron chelators, lazaroids 
and phenyl-t-butyl-nitrone. Tirilazad, a lipid peroxidation inhibitor, which 
had been found to reduce infarct size in several stroke models (Xue et al., 
1992), did not show improved functional outcome in patients with acute 
cerebral ischaemia (Peters et al., 1996), although a larger trial using higher 
doses is in progress. Phenyl-t-butyl-nitrone, a spin-trapping agent has been 
shown to reduce damage in animal stroke models, supporting the concept 
that free radicals contribute to brain injury (Floyd R.A et al. 2002). 
 
Antioxidants are normally molecules or compounds that can attenuate the 
damage caused via oxidative stress, for example in lipid peroxidation. They 
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function by reacting to intermediate peroxy radicals (Halliwell, 1992). An 
important exogenous antioxidant in the brain is α-tocopherol. Although the 
levels of this agent take a considerable time to increase in the brain tissue 
after vitamin E supplementation, it has been found that severe and prolonged 
deprivation of this antioxidant produces pronounced neurological 
derangements (Muller & Goss-Sampson, 1990). Also considering that lipid 
peroxidation is not the sole end result of oxidative damage (Halliwell, 1992), 
the implication is that these anti-lipid peroxidant may not be as effective in 
limiting tissue damage. 
 
N-acetyl-5-methoxytryptamine (melatonin) an example of an endogenous 
antioxidant that is produced in the pineal gland of all mammalian species, 
including humans (Reiter, 1991). This neuro-hormone has been implicated 
as a powerful quencher of free radical generation at high concentration and 
functions as a prooxidant at lower concentrations (Ianas, O., et al. 1991). 
The pineal gland and melatonin is discussed in more details in section 1.5. 
 
This suggests an important role of antioxidants in limiting tissue damage 
mediated by oxidative stress. 
 
1.5. THE PINEAL GLAND 
1.5.1. INTRODUCTION 
The pineal gland, in man, was first discovered by the famous anatomist, 
Herophilos (325-280 B.C.) at the University of Alexander in Egypt (Reiter 
RJ, 1980). Subsequently, in the late 19th century and the beginning of the 
20th century, there was an explosion in pineal organ research.  
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In the last 50 years, scientists have established that the pineal gland is an 
endocrine organ. The neuronal connections linked to the pineal gland and 
the discovery of melatonin, the chief hormone produced by this gland 
stimulated worldwide research in this field. 
 
1.5.2. STRUCTURE AND LOCATION OF THE PINEAL  
The pineal gland is located within the brain. It varies in size, shape and 
location in different organisms. In humans, the gland is situated on the 
dorsal surface of the hypothalamus, occupying a central position between the 
two cerebral hemispheres (Ebadi, M, 1993). 
 
It is a highly vascularised tissue consisting of two types of cells, 
pinealocytes and neuroglia. In humans, pinealocytes predominate and 
produce both melatonin and peptides e.g. arginine-vasotocin (Brzezinski, 
1997). 
 
In the rat, the pineal is located in the superior part of the sulcus transverses 
cerebri at the surface of the brain. It lies between the cerebral hemispheres, 
anteriorly, and posterior to the cerebellum. The pineal gland is connected to 
the commissural region by a thin filament-like stalk (Figure 1.10.). The 
pineal gland is attached to the brain by the pineal stalk, and it consists of 
pinealocytes, pinealoblasts and fibrocytes. 
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Figure 1.10. Transverse section of the rat brain showing the relative position 
of the pineal body and pineal stalk (Rowett, 1962). 
 
1.5.3. PINEAL INNERVATION 
 
The pineal gland in mammals is heavily innervated by norepinephrine 
containing sympathetic fibres (Guerillot C et al., 1979). It was also 
demonstrated by Wolfe et al. (1962) that the secretory functions of the gland 
was linked to its sympathetic connections. In addition, the gland is also 
termed as the “neuroendocrine transducer organ”, due to its capability to 
synthesise and release melatonin in response to a neuronal stimulus. An 
external light stimulus that is converted to photic signals in the retina, pass 
through the suprachiasmatic nucleus (SCN), to the tubural hypothalamus, 
over the medial forebrain bundle, reticular formation and upper thoracic 
intermediolateral cell column, to the superior cervical ganglion. The latter 
conveys the signal via the postganglionic sympathetic fibres to the conarian 
nerve, which in turn passes the signal to the pineal gland. The pineal gland 
subsequently releases norepinephrine, which binds to the β-adrenergic 
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receptors present on the pineal cell surface. The result is a cascade of events 
leading to the production of melatonin (Ebadi et al. 1986). 
 
1.5.4. PINEAL INDOLE METABOLISM 
 
The pineal gland secretes melatonin, which is an indoleamine (Lerner et al., 
1958). Tryptophan is taken up from the blood stream into the pinealocytes 
and utilized in the synthesis of pineal proteins. Most of the tryptophan is 
converted to 5-hydroxytryptophan by the action of the enzyme tryptophan 
hydroxylase in the mitochondria (Hori et al., 1976). 5-hydroxytryptophan is 
then converted by L-amino decarboxylase to serotonin (5HT), also referred 
to as 5-hydroxytryptamine (Snyder et al., 1965). 
 
The 5HT produced can in turn undergo three different metabolic pathways 
(Figure 1.11.) to produce the following metabolites by the action of specific 
enzymes: 
 
1. N-acetylserotonin which is the precursor of melatonin (Klein et al., 
1971). 
2. 5-hydroxyindole acetaldehyde which can further be metabolised, 
due to its unstable nature and normally exists as an intermediate. It is 
converted to 5-hydroxyindoleacetic acid (Wurtman & Larin, 1968) 
and 5-hydroxytryptophol which is further methoxylated to form 5-
methoxytryptophol (Wurtman & Axelrod, 1967). 
3. 5-methoxytryptamine. 
The detailed reaction schemes can be seen in Figure 1.11. 
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Figure 1.11. Shematic representation of pineal indole metabolism (modified 
from Young & Silman, 1982) 
 
1.5.5. MELATONIN 
1.5.5.1. History of melatonin 
For quite a long time it was known that a substance is produced by the 
mammalian pineal gland that causes the blanching of melanophores in 
amphibian skin. In 1917, McCord and Allen demonstrated that extracts of 
the pineal gland cause the skin of tadpoles to lighten. A major breakthrough 
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in pineal studies occurred in 1958 when the dermatologist Aaron Lerner and 
co-workers (1958) extracted bovine pineal glands and were able to isolate a 
skin lightening compound, and determine its structure (1959) after 4 years of 
work and the use of more than 250 000 pineal glands (Lerner 1999). It was 
identified to be N-acetyl-5-methoxytryptamine, and due to its blanching 
effect on melanophores, it was named melatonin. It’s chemical structure is 
shown in Figure 1.12. 
 
NH
CH2CH2NHCOCH3
CH3O
Melatonin  
 
Figure 1.12. The chemical structure of melatonin (Feuer, 1990) 
 
1.5.5.2. Functions of melatonin in the mammalian system 
 
Ianas et al. (1991) were the first to report melatonin’s antioxidant action. 
The agent exhibited antioxidant actions when its concentration exceeded 
0.25 mM, and at concentrations below that, melatonin was reported to be 
prooxidative. 
 
Tan et al. (1993) reported that melatonin was a more powerful free radical 
scavenger relative to known scavengers such as mannitol and GSH and in 
addition, melatonin was a more effective OH. scavenger when compared to 
serotonin, N-acetylserotonin or 5-methoxytryptamine, all structurally related 
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to melatonin. These structure-activity studies showed that the 5-methoxy 
group on melatonin’s indole nucleus and the N-acetyl group on the side 
chain, are both important for this property of melatonin. Melatonin is the 
most potent hydroxyl radical scavenger (Reiter et al., 1994) and it has also 
been established that melatonin scavenges the peroxyl radical (ROO.) 
(Melchiorri et al., 1995).  
 
Melatonin’s free radical scavenging action occurs in a two-step process 
(Figure 1.13.): In the first step, the melatonin molecule donates an electron 
to the OH. radical, to produce an indolyl cation radical. The second step 
consists of the oxidation of the indolyl cation radical, by the O2.- to form 5-
methoxy-N-acetyl-N-formyl-kynuramine and the proposed mechanism by 
which melatonin acts as a free radical scavenger (Hardeland et al., 1993) can 
be seen in Figure 1.13. Melatonin is thus a suitable antioxidant due to its 
ability to terminate free radical chains and not to participate in redox 
cycling. 
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Figure 1.13. The proposed mechanism by which melatonin acts as a free 
radical scavenger (Hardeland et al., 1993) 
 
When Reiter et al. (1997) examined the antioxidant properties of melatonin 
in rats treated with Safrole. Safrole is a known carcinogen that causes DNA 
damage as a consequence of free radical generation. The results of the 
experiment showed that when melatonin was co-administered, it reduced the 
DNA adduct formation, confirming its antioxidant actions. 
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Melatonin was also found to stimulate the activity in the brain of glutathione 
peroxidase (GSHPx). GSHPx metabolises H2O2 to H2O, thereby reducing 
the production of toxic OH. (Reiter, 1997). Melatonin can also stimulate 
hepatic and cerebral glucose-6-phosphate dehydrogenase activity in mice, 
increasing NADPH levels. This promotes the enzymatic production of GSH 
via glutathione reductase. GSH is an important co-factor for GSHPx. 
(Pierrefiche & Laborit, 1995). This implies that melatonin possesses both 
direct and indirect antioxidant properties, thus making it a potent antioxidant 
in the mammalian system. 
 
1.6. OBJECTIVES 
 
The objectives of this study are to determine whether phenytoin could act as 
a neuroprotective agent and secondly to attempt to expose the mechanism of 
neuroprotection, should it occur. 
 
The potential neuroprotective properties of phenytoin were investigated: 
 
I. By determining whether this agent can protect the hippocampus under the 
insult of QUIN in an in vivo situation. This was done by histological 
examination of the hippocampal area of the brain under the insult of QUIN 
in phenytoin free and phenytoin pre-treated rat brains using stereotaxic 
techniques. 
 
II. By assessing its free radical scavenging properties using the NBT assay 
with cyanide as the neurotoxin in whole rat brain homogenate. 
 
III. The ability of the drug to prevent lipid peroxidation in whole rat brain 
homogenate incubated with the neurotoxins QUIN and Iron (II). 
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IV. The interaction of the drug with iron (II) and (III) ions using UV, IR 
analysis and electrochemical detection. 
 
V. By determining its influence on the pineal gland on the release of the 
endogenous antioxidant, melatonin and the other indoleamines. 
 
QUIN which acts at the NMDA receptor was chosen because it is an 
endogenous compound that is extremely neurotoxic, and is thought to play a 
role in the pathology of numerous neurodegenerative diseases such as 
Huntington’s disease, AIDS related dementia. Its level is also found to 
increase during seizures which results in area specific neuronal damage. 
 
In addition phenytoin protects the brain against a broad spectrum of 
neurological injuries resulting from strokes, ischaemic episodes (Vartanian 
M G et al. 1996) and has been used in an attempt to prevent post-traumatic 
epilepsy, which is thought to happen after neuronal degeneration (Iudice A. 
et al., 2000). This agent acts as a neuroprotectant due to its anti-seizure and 
sodium channel antagonistic properties in neurons. New compounds such as 
free radical scavengers and antiperoxidants, show encouraging experimental 
results, but their clinical use is still very limited. 
 
It is hoped that this investigation will expose certain underlying mechanisms 
by which phenytoin offers neuroprotection and also help to better understand 
the factors that might contribute towards neurodegeneration caused by an 
increase in QUIN and free iron levels in the brain. 
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CHAPTER 2 
 
EFFECT OF QUINOLINIC ACID AND PHENYTOIN ON 
HIPPOCAMPAL NEURONS 
 
2.1.   INTRODUCTION 
 
In previous studies it had been demonstrated that QUIN induces neuronal 
cell death in primary neuronal cell cultures and also causes degeneration of 
neurons of the hippocampal areas after directly injecting the neurotoxin in 
that particular area (Southgate et al. 1999). It is also known that phenytoin, 
being a sodium channel blocker, is able to protect neurons to a certain 
degree after trauma and ischaemic episode (Boxer PA et al., 1990). 
 
Quinolinic acid is an agonist of the neuronal NMDA receptor (Stone, T.W. 
& Perkins, M.N. 1981), which has been detected in both the human and rat 
brain (Williams, K., et al., 1991). Intrastriatal and intrahippocamal injections 
of QUIN into the rat brain have been shown to induce neuronal lesions 
(Schwarcz, R., et al., 1983). 
 
Moreover there is increasing evidence that during trauma, inflammation and 
HIV infections there is an increase in concentrations of EAAs more 
specifically QUIN, which induces neurotoxicity and is thought to cause 
certain types of dementia (Heyes & Morrison 1997). 
 
The role of QUIN in physiology is not yet very clear, while in pathology an 
abnormal accumulation of QUIN in the brain has been proposed as one of 
the causes of convulsions (Lapin, 1981), Huntington’s disease (Beal et al. 
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1986), hepatic encephalopathy (Moroni et al.1986b, c) and recently also 
AIDS-related neurological disorders (Brown, 1990).  
 
2.1.1. STRUCTURE AND FUNCTION OF THE 
HIPPOCAMPUS 
 
The hippocampus is a region of the brain, situated medial to the lateral 
ventricle in the medial temporal lobe. This region forms part of the cerebral 
cortex, which is folded onto itself in a peculiar shape (Bear et al., 2001). 
After a Nissl-staining of the coronal section of the caudal telencephalon of a 
rat brain (Figure 2.1) this structure mentioned above can be clearly 
distinguished. The glutamatergic system, requiring glutamate as the main 
neurotransmitter, is the main pathway that is involved in the functioning of 
the hippocampus. This chemical messenger causes the activation of 
postsynaptic NMDA receptors involved in memory and learning.  
 
 
 57
Chapter 2                                                                          Histological studies 
 
 
Figure 2.1. A coronal section through the caudal telencephalon of a rat brain 
displaying the hippocampal structure and the three subdivided regions. 
(www.bio.davidson.edu/courses/genomics/method/Brainparts.html) 
 
The hippocampus consists of two thin sheets of neurons, namely the dentate 
gyrus and the Ammon’s horn, folded onto each other. The Ammon’s horn is 
divided into four areas, of which the most important are the CA1 and CA3 
regions as shown in Figures 2.1. and 2.2. The major input to the 
hippocampus is the entorhinal cortex, which sends information to the 
hippocampus through a bundle of axons called the perforant path. These 
axons are connected to the neurons of the dentate gyrus via synapses. The 
dentate gyrus neurons give rise to axons referred to as mossy fibres which 
provide synaptic connection to the cells in the CA3 region. The CA3 cells in 
turn give rise to two axonal branches, namely the formix and Shaffer 
collateral, which synapses on the neurons of the CA1 region (Figure 2.2) 
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Figure 2.2. An illustration of some microcircuits on the hippocampus (Bear, 
et al., 2001) 
 
2.2.   HISTOLOGICAL INVESTIGATION 
 
2.2.1.  INTRODUCTION 
 
Histology is derived from the Greek word for web or tissue, and involves the 
examination of preserved, sectioned and stained tissues. Most of our 
knowledge of internal tissue structure has come from this branch of science 
(Hodgson, A.N. & Bernard, R.T.F. 1992). 
 
In this experiment it was decided to investigate whether phenytoin offered 
neuroprotection against QUIN-induced intra-hippocampal lesions in the rat 
brain. After treatment, the hippocampus of the rats was sectioned and 
examined microscopically for evidence of any morphological changes. The 
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hippocampus was selected as it is very densely populated with glutamate 
receptors, and is also known to be susceptible to QUIN attack. Moreover, 
damage to this area correlates well with the symptoms observed in patients 
suffering from neurodegenerative diseases such as Huntington’s disease 
(Beal, M.F., et al. 1986, Popoli, P et al, 1994). 
 
2.2.2.  MATERIALS AND METHODS 
 
2.2.2.1.  Chemicals and reagents 
 
Quinolinic acid and phenytoin were purchased from Sigma Chemical 
Company (USA). Paraffin wax was obtained from Lasec (South Africa). 
Cresyl violet stain was purchased from BDH Chemicals Ltd (England), 
while DPX was purchased from Philip Harris Ltd (England). Haupt’s 
adhesive consisted of the following; 1 g gelatine, 100 ml water, 2 g phenol 
and 15 ml glycerol. Sodium Phenobarbitone was purchased from Merck 
(Germany). All other chemicals were of the highest quality available and 
were purchased from commercial distributors. 
 
2.2.2.2.   Animals 
 
Adult male Wistar rats, purchased from the South African Institute for 
Medical Research (Johannesburg, South Africa) were used throughout the 
study. The animals were housed under artificial illumination with a daily 
photoperiod of 12 hours (lights on at 06h00). The animal-house temperature 
was maintained at a constant 20oC to 24oC, while an extractor fan ensured 
the constant removal of stale air. The rats were housed four per cage with 
food and water provided ad libitum. 
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2.2.2.3.  Surgical procedures 
 
I. BILATERAL INTRAHIPPOCAMPAL INJECTIONS OF QUINOLINIC 
ACID 
 
Male rats were anaesthetised with sodium phenobarbital (60 mg / kg i.p.) 
and placed in a stereotaxic frame. The rat skull was orientated according to 
the König and Klippel stereotaxic atlas. After a sagittal cut in the skin of the 
skull, the bregma suture was located and holes were drilled with an electrical 
trepan drill at the following co-ordinates; 4.4 mm anterior, 2 mm lateral of 
the sagittal suture. The bregma suture can be seen in Figure 2.3. Care was 
taken not to lesion the meninges. A Hamilton syringe, with a cannula of 
diameter 0.3 mm, was used to inject 250 nmol of quinolinic acid in 2 µl of 
PBS, 3 mm ventral of the dura. The injection was administered at a rate of 1 
µl per minute and the cannula was left in situ for a further 3 minutes 
following the drug injection, to allow for passive diffusion away from the 
cannula tip and to minimise spread into the injection tract. The cannula was 
then slowly removed and the scalp was closed with sutures. Animals were 
kept in an incubator (37oC) until they recovered from the anaesthesia. 
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Figure 2.3. A view of the rat skull, exposing the reference point for the measurement of 
the coordinates, after the skin has been cut. 
 
II.  SHAM LESIONED RATS 
 
Rats to be used as controls were subjected to the surgical procedures 
outlined in section 2.2.2.3(I). However, stereotaxic injections into the 
hippocampus were free of QUIN, and comprised only of PBS at a pH of 7.4. 
 
2.2.2.4.  Treatment regimens 
 
Animals were divided into three groups as shown in Table 2.1. Ethyl Oleate 
was administered sub-cutaneously at the same dosage as that given to the 
rats treated with phenytoin. QUIN was dissolved in PBS made up to pH 7.4. 
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Table 2.1:Treatment regimen with phenytoin and QUIN for each group of 
animals 
 
GROUP Received intra- 
peritoneally for 5 
days prior to 
surgery 
Intra-
hippocampal 
injection consisted 
of:- 
Received daily 
doses for 2 days 
after surgery  
 
CONTROL Ethyl oleate and 
ethanol 
 
PBS Ethyl oleate and 
ethanol 
PHENYTOIN Phenytoin (20 
mg/kg) in ethyl 
oleate and ethanol 
500 nmol QUIN in 
2 µl of PBS 
Phenytoin (20 
mg/kg) in ethyl 
oleate and ethanol 
NO 
PHENYTOIN 
Ethyl oleate and 
ethanol 
 
500 nmol QUIN in 
2 µl of PBS 
Ethyl oleate and 
ethanol 
 
Animals were treated for 2 days following surgery. Injections of ethyl oleate 
vehicle or phenytoin were administered at the same time (12h00) each day, 
so as to maintain a steady-state concentration in the CSF. 
 
2.2.2.5.  Brain removal 
 
Rats were sacrificed by neck fracture and decapitated. The brain was 
exposed by making an incision through the bone on either side of the parietal 
suture from the foramen magnum to near the orbit. The calvarium was 
removed, exposing the brain. The brain was easily removed for use in 
experiments. 
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2.2.2.6.  Histological techniques 
 
I. Fixing the brain 
 
Immediately after death, animal tissues begin to break down as a result of 
autolysis and bacterial attack. Fixation functions to chemically stabilise 
proteins, and thus preserve their structures. Brains were removed from the 
skull as in section 2.2.2.5, and rapidly fixed in a mixture of formaldehyde 
(30%), glacial acetic acid, and ethanol (2:1:7 v/v) for 2 hours. After fixation, 
the brains were stored in 70% ethanol and processed as mentioned in Table 
2.2. 
 
II. Specimen preparation and embedding 
 
In order to be cut, the slices need to be supported. Embedding involves the 
infiltration and orientation of tissue in the paraffin wax support medium. The 
tissue was dehydrated using increasing concentrations of ethanol, followed 
by the removal of the ethanol using xylene. Finally the tissue was immersed 
in molten paraffin wax, which removed the xylene, while infiltrating the 
tissue without encountering water. The method used is shown in Table 4.2. 
 
Table 2.2: Procedure for embedding brain in paraffin wax 
 
STEP PROCESSING AGENT TIME 
1 Ethanol 1 hour 
2 Ethanol 1 hour 
3 Absolute Ethanol  I 1 hour 
4 Absolute Ethanol II 1 hour 
5 Xylene I 1 hour 
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6 Xylene II 1 hour 
7 Melted Paraffin Wax I (570C) 1 hour 
8 Melted Paraffin Wax II (570C) 1 hour 
 
 III. Blocking out 
 
The brain material was fixed into a block so that it could be cut with a 
microtome. A mould was formed from two L-shaped metal bars. These were 
coated with ethanol: glycine to prevent the block sticking to the mould. A 
little molten wax was added to the mould and allowed to harden. The brain 
was removed from the final molten wax stage (previous section) and placed 
into the mould with warmed forceps. The brain was then completely covered 
in molten wax. Air was gently blown over the surface of the wax until the 
top solidified. The whole mould was then immersed in a large dish of cold 
water. This was to enable the wax to solidify quickly, and prevent the 
formation of crystals that might have disrupted the tissue. The blocks were 
left overnight in cold water to ensure that the wax had completely solidified. 
 
IV. Sectioning 
 
The wax block was trimmed with a razor blade so that two of the sides were 
parallel, while the other two converged slightly. The sides were cut so as to  
leave about 2 mm of wax around the tissue. The wax block was attached to a 
small wooden block with a small amount of molten wax. 
 
Sectioning was done using a rotary microtome. The microtome was set to 
cut sections of 5 µm thickness. As sections were cut they would stick to one 
another, so as to form long ribbons. When the part of the brain containing 
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the hippocampus was reached, every second section was removed and 
placed in a water bath (25oC) using a paintbrush. 
 
V. Transferring sections to slides 
 
Four to five sections at a time were removed from the water bath and placed 
onto microscope slides containing a thin layer of Haupt’s adhesive. The 
slides were left overnight in an oven, which had a saturated atmosphere of 
formaldehyde and the temperature was maintained at 40oC. 
 
VI. Staining 
 
The sections were Nissl stained using cresyl violet. This stains Nissl 
substances intense purple, the nuclei purple and leaves the background clear 
(Bauer, J.D., et al. 1974) 
 
Before the section could be stained, it first had to be dewaxed and 
rehydrated as the stain is water-soluble. This was done as per Table 2.3. 
 
 
Table 2.3: Procedure for dewaxing and rehydrating brain sections 
 
STEP PROCESSING AGENT TIME 
1 Xylene I (dewaxing) 5 minutes 
2 Xylene II 5 minutes 
3 Xylene / Absolute Ethanol (1:1) 3 minutes 
4 Absolute Ethanol Overnight at 300C 
 
Sections were stained by placement in a 0.1% cresyl violet solution for 2 
hours. The slides were differentiated rapidly in 95% ethanol by rinsing in a 
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flat dish until the background was clear. Sections were then dehydrated 
again as shown in Table 2.4. 
 
Table 2.4: Procedure for dehydrating brain sections after staining 
 
STEP PROCESSING AGENT TIME 
1 Absolute Ethanol I 5 minutes 
2 Absolute Ethanol II 5 minutes 
3 Xylene I 5 minutes 
4 Xylene II 5 minutes 
  
VII. Mounting of the slides 
 
While the slides were kept moist with xylene, enough DPX was added to 
just cover the tissue. A cover slip was placed over the tissue. The slides were 
then allowed to dry on a flat surface for 48 hours. 
 
2.2.2.7.  Photo-microscopy 
 
The slides were photographed using a combination of an Olympus digital 
camera and light microscope at a magnification of 1000 times. 
 
2.2.3.  RESULTS 
 
The area of the hippocampus that was investigated was adjacent to the site of 
injection of QUIN where no necrosis of neurons was visible. Samples that 
may have been physically damaged by the cannula were not selected. All 
damage that resulted was therefore of a neurochemical nature and not a 
result of physical damage caused by the cannula. 
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Neurons in the CA1 and CA3 regions of the hippocampus were examined. 
From the control group, injected intra-hippocampally with PBS, the neuronal 
cells from the CA1 region (Figure 2.4.) and CA3 region (Figure 2.6) 
appeared to be undamaged. Neurons from animals treated with QUIN 
showed signs of degeneration by virtue of their roundness and swelling in 
the CA1 region (Figure 2.5), while the CA3 region (Figure 2.7) showed 
signs of degeneration and necrosis. The neurons in the CA1 region (Figure 
2.5) and those in the CA3 region (Figure 2.7) of those animals treated 
concomitantly with the neurotoxin, QUIN and phenytoin, appeared to be less 
damaged relative to the rats injected with QUIN only. In addition a higher 
degree of protection could be noted in the CA1 region as compared to the 
CA3 regions of the rat hippocampus.  
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Figure 2.4. The CA1 region of rat brain, injected with PBS only, cells have 
distinct pyramidal shape and morphology (Magnification × 1000). 
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Figure 2.5. (Top) CA1 regions of rat brain injected with QUIN only. 
Swelling and necrosis of neurons are visible. (Bottom) CA1 regions of rat 
brain pretreated with phenytoin and injected with QUIN intra-
hippocampally. Cells appear less swollen and more integrity was retained 
(Magnification × 1000) 
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Figure 2.6. CA3 region of rat brain, injected with PBS only, cells have 
distinct pyramidal shape and morphology suggesting no major damage 
(Magnification × 1000). 
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Figure 2.7. (Top) CA3 regions of rat brain injected with QUIN only. 
Swelling and necrosis of neurons are visible. (Bottom) CA3 regions of rat 
brain pretreated with phenytoin and injected with QUIN intra-
hippocampally. Cells appear less swollen and more integrity was retained 
(Magnification × 1000). 
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2.2.4. DISCUSSION 
 
QUIN induced considerable damage to the CA1 and CA3 regions of the 
hippocampus as seen in Figures 2.5. and 2.7. The damage by this neurotoxin 
is thought to be dependent on the NMDA receptors, an NMDA antagonist 
prevents this damage (as discussed in section 1.3.4). The activation of the 
NMDA receptors results in an influx of Na+ ions into the cells causing a 
depolarisation of the membrane. This further results in the deactivation of 
the magnesium block, thus mediating the opening of the channel. In 
addition, this allows Ca2+ ions to move through into the neuronal cells.  
 
As mentioned in section 1.2.3, acute toxicity results from excessive 
activation of the glutamate receptors. This type of toxicity can be attributed 
to the rapid influx of Na+ ions into the neuron, which subsequently allows 
passive diffusion of Cl- ions, both of the processes resulting in a change in 
osmotic pressure and allowing an inward movement of water molecules. 
This eventually results in osmotic lysis of the cell (Southgate, 1999). Thus 
two main processes contribute to the toxicity of QUIN. Firstly, over-
stimulation of the neuron usually causes a prolonged depolarisation that 
results in depletion of energy reserves and secondly due to Ca2+ 
accumulation, which happens because of the Na+ influx via the Na+/Ca2+ 
exchanger. This increase in intracellular Ca2+ levels can also initiate a chain 
of events culminating in free radical generation. All of the above mentioned 
processes together with the osmotic water intake result in the swelling and 
cell damage observed in the photomicrographs in Figure 2.5 and 2.7. of the 
animals treated with QUIN only. 
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In the rats treated with both QUIN and phenytoin, the degree of damage to 
the areas of the hippocampus viewed, was lesser than the rats treated with 
QUIN only. This can be seen in Figures 2.5 and 2.7. This is believed to be 
mainly due to the Na+ channel blocking properties of this antiepileptic drug. 
This property of phenytoin reduces the excitability of the neurons which, as 
stated above can lead to cell damage. 
 
Furthermore, phenytoin might also act through other mechanisms such as 
scavenging free radicals or by interfering with the events leading to their 
formation. Phenytoin may also prevent lipid peroxidation by stabilization of 
the neuronal cell membranes. These processes could contribute to the 
maintenance of the cell integrity to a higher extent in the rats treated with 
both phenytoin and QUIN as compared to the ones treated with QUIN only. 
 
The next two chapters examines the free radical scavenging properties of 
phenytoin and its effects on lipid peroxidation in whole rat brain 
homogenate.
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CHAPTER 3 
SUPEROXIDE ANION GENERATION 
3.1. INTRODUCTION 
Reactive oxygen species are continually generated intracellularly in aerobic 
organisms. If allowed to react uncontrollably, these are capable of causing 
extensive damage to DNA, carbohydrates, proteins and lipids within the cell 
(Hugon, J et al., 1996). Cells possess highly effective antioxidant defence 
mechanisms to protect neurons against free radical species (Braughler, J.M. 
& Hall, E.D. 1989). These protective mechanisms can be classified into two 
main categories (Dawson, V.L. & Dawson, T.M. 1996), namely the 
enzymatic defence mechanisms, which include superoxide dismutase, and 
the non-enzymatic cellular antioxidants, which include Vitamins A and E. 
Under normal conditions these defence mechanisms are quite capable of 
protecting neurons, but under conditions of excessive ROS production, these 
mechanisms may not be able to cope and neurotoxicity may result (DiFiglia, 
M., 1990). ROS are generated by the addition of a single electron to O2.. The 
radical is usually generated as a result of electron “leakage” from the 
electron transport chain located in the mitochondria (McCord, J.M., 1985), 
and by activation of certain enzymes. One of the by-products of the activities 
of these   enzymes is the production of O2-. superoxide anions, which can be 
very reactive and can lead to neurodegeneration (Patel, M., et al. 1996).  
 
In this experiment cyanide was used to generate the superoxide radicals. 
Cyanide is a known neurotoxin and the primary mechanism of action of this 
neurotoxic agent involves the inhibition of cytochrome oxidase aa3, the 
terminal oxidative enzyme of the electron transport chain (Albaum, H.G., et 
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al., 1946, Isom, G.E & Way, J.L., 1984). Studies have revealed that the 
sequence of reactions that follow cyanide-induced histotoxic hypoxia 
demonstrate that KCN produces elevated levels of brain calcium (Johnson, 
J.D., et al., 1986). Moreover there is also an increase in free cytosolic 
calcium in an isolated neuronal cell model (Johnson, J.D., et al., 1987). This 
elevation in calcium in the cytosol is associated with free radical generation 
and subsequent damage to cells. In addition, a number of antioxidant 
enzymes are also reported to be inhibited by cyanide, thus again it is 
believed that this further potentiates the oxidative stress and subsequent 
neurotoxicity of this agent (Ardelt et al., 1989). 
 
In this study, it was investigated whether the known antiepileptic agent 
phenytoin has the ability to either scavenge or reduce the production of these 
superoxide free radicals.  
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3.2. EXPERIMENT 1: The effect of phenytoin on cyanide 
induced superoxide anion formation in whole rat brain 
homogenate 
 
3.2.1.  INTRODUCTION 
 
The nitro-blue tetrazolium (NBT) assay, which is generally accepted [Ottino, 
P. & Duncan, J.R. 1997] to be a reliable method for assaying for superoxide 
anions, was used. The assay involves the reduction of the NBT ion to the 
insoluble diformazan form, which can be extracted with glacial acetic acid 
and the absorbance read at 560 nm. 
 
3.2.2.  MATERIALS AND METHODS 
 
3.2.2.1.  Chemical reagents 
 
Nitro-blue tetrazolium (NBT), Nitro-blue diformazan (NBD), potassium 
cyanide (KCN) and phenytoin were purchased from the Sigma Chemical 
Company (USA). Glacial acetic acid was purchased from Holpro Chemical 
Company (South Africa). All other chemicals used were of the highest 
quality available from commercial sources. 
 
3.2.2.2.  Preparation of standards 
 
NBD was used as a standard. A series of reaction tubes, each containing 
appropriate aliquots of NBD dissolved in acetic acid was prepared. A 
standard curve (see Appendix 1) was determined by measuring the 
absorbance at NBD concentration intervals of100 µM. The absorbance was 
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read in plastic cuvettes having a path length of 1 cm at 560 nm using a 
Varian Cary 500 Scan UV-VIS NIR Spectrophotometer (EL 99053199) 
 
3.2.2.3.  Preparation of whole Rat brain Homogenate 
 
Adult, male Wistar rats were used for the experiment. These were cared for 
as explained in section 2.2.2.2. On the morning of the experiment, the brains 
were removed as described in section 2.2.2.5. The whole brains were 
homogenised in a Teflon® coated glass homogeniser for 60 seconds on ice. 
A 10% w/v homogenate was prepared with 0.1M PBS of pH 7.4. 
 
3.2.2.4. The Nitro-blue tetrazolium assay 
 
A modified method of Ottino and Duncan (1997) was used for this assay. A 
0.1% NBT solution was made by dissolving the NBT in ethanol before 
making up to the required volume with Milli-Q water. All the other reagents 
used were dissolved only in Milli-Q water. The final ethanol concentration 
in the incubation flasks was less than 1.5%. 
 
To 1 ml samples of brain homogenate, 0.4 ml of the 0.1% NBT solution and 
different concentrations of phenytoin (0, 0.25, 0.50, 0.75, 1.0 and 1.25 mM) 
and KCN (0, 0.25, 0.5, 1mM) being tested were added and allowed to 
incubate for 60 minutes at 37oC in an oscillating water bath. On termination 
of the incubation, the suspensions were centrifuged at 2000 x g for 10 
minutes. The supernatant was poured off and the pellet was dissolved in 2.0 
ml glacial acetic acid. 
 
The relative absorbance of the glacial acetic fraction was measured at 560 
nm and converted to µmoles diformazan using a standard curve generated 
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from NBD. Final results were expressed as µM diformazan produced / mg 
wet tissue.  
 
3.2.2.5.  Statistical analysis 
 
All data are represented as means ± SD from six determinations. Statistical 
analysis was performed using a one-way analysis of variance (ANOVA) 
followed by the Student– Newman–Keuls multiple range test. Values were 
accepted as being statistically significantly different if a P value was < 0.05.  
 
3.2.3. RESULTS 
 
Exposure of the whole rat brain homogenate with various concentrations (0–
1 mM) of KCN increased superoxide anion production in a concentration 
dependent manner (Figure 3.1). Furthermore, phenytoin did not cause a 
significant reduction in superoxide generation with 0.5 mM and 1.0 mM 
cyanide concentrations in the incubation vessels as seen in Figures 3.2. and 
3.3, respectively. 
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Figure 3.2. Effect of Phenytoin on 0.5 mM KCN- induced superoxide 
production in whole rat brain homogenate. Each bar represents the mean ± 
SD of six determinations. *(p<0.05); Students Newman Keuls multiple 
range test. 
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Figure 3.3. Effect of Phenytoin on 1.0 mM KCN- induced superoxide 
production in whole rat brain homogenate. Each bar represents the mean ± 
SD of six determinations. *(p<0.05); Students Newman Keuls multiple 
range test. 
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3.2.4.  DISCUSSION 
 
The significance of free radical generation has been studied in the 
pathophysiology of many neurological disorders where there is massive 
neuronal loss. The production of superoxide in rat forebrain homogenate was 
significantly increased as expected by exposure to KCN and as reported by 
Lambat et al. (2000). 
 
Moreover this dose-dependent increase in levels of NBD with KCN can be 
directly linked to the amount of superoxide radical produced as more NBT 
was reduced to produce the reduced form of the compound, NBD. However 
the increase in NBD levels was not significantly lowered by the antiepileptic 
drug phenytoin at concentrations of between 0 and 2.0 mM of this drug in 
the presence of 0.5 mM and 1.0 mM KCN.  
 
These results therefore demonstrate that phenytoin was not able to act as a 
superoxide anion scavenger or chemically react with KCN to make cyanide 
unavailable to produce toxicity.  
 
Another possibility is that phenytoin may react with superoxide anions 
formed and the product of this reaction could be a free radical of phenytoin. 
A free radical of phenytoin could thus have favoured the reduction of NBT 
accounting for the elevated levels of NBD observed in all the reaction tubes 
as compared to the control.
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CHAPTER 4 
LIPID PEROXIDATION 
4.1.   INTRODUCTION 
In all living cells, the cell membrane separates the cell interior from the 
external environment, and in addition functions to hold and contain the 
internal structures of the cell. Membranes are not stagnant boundaries that 
segregate regions, but are dynamic systems responsible for among other 
things; the production of ATP, the discriminating transport of substances 
into and out of the cells, the binding of regulatory agents (such as hormones 
and growth factors), and the binding of neurotransmitters that mediate the 
conduction of nerve impulses (Dykens, J.A., et al. 1987). 
 
Membranes are composed chiefly of protein and lipid molecules. The fluid 
mosaic model of membrane structure proposed by Singer and Nicholson 
(Singer, S.J. et al. 1972) is the accepted model of membrane structure. 
Membranes are understood to consist of a lipid bi-layer containing a mixture 
of proteins and carbohydrates. 
 
Changes in membrane fluidity through physical and chemical disturbances, 
e.g. oxidative stress, can cause changes to neuronal characteristics, and the 
activities of the transport proteins. Neuronal membranes are especially 
vulnerable to free radical mediated oxidative stress, since the brain 
consumes 20% of the total body oxygen, is relatively deficient in protection 
mechanisms such as glutathione and vitamin E, and contains large amounts 
of polyunsaturated lipids (Reiter, R.J., et al. 1996). The oxidative destruction 
of polyunsaturated fatty acids is known as lipid peroxidation, and is 
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enormously damaging as a result of the self-perpetuating chain reactions 
they cause (Fahn, S. et al. 1992). Since some free radical production is 
inevitable in cells, several enzymatic and non-enzymatic defence 
mechanisms have evolved to protect cells. As discussed in section 1.4.3, any 
alterations either in the defence mechanisms or the production of free 
radicals, could upset this balance and lead to neurotoxicity. 
 
This series of experiments were conducted to investigate the effect of 
phenytoin on QUIN and iron-induced lipid peroxidation in whole rat brain 
homogenate. The thiobarbaturic acid (TBA) assay was used to determine 
lipid peroxidation. The principle of the experiment involves the reaction of 
malondialdehyde (MDA) and 4-hydroxyalkenals (4-HDA) with TBA to 
yield a pink complex, which can be extracted with butan-1-ol and read at 
532 nm. MDA and 4-HDA are degraded lipid products from cell 
membranes, and are taken as reliable indicators of oxidative stress (Reiter, 
R.J., et al. 1995; Packer, L et al. 1990). 
 
4.2. MATERIALS AND METHODS 
 
4.2.1.  CHEMICAL REAGENTS 
 
Butylated Hydroxytoluene (BHT) and 2-Thiobarbaturic acid (TBA) were 
purchased from the Sigma Chemical Company (USA). 1,1,3,3-
Tetramethoxypropane was obtained from Fluka AG (Switzerland). Butan-1-
ol was supplied by Holpro Chemical Company (South Africa). Ascorbic 
acid, Fe2SO4, Trichloroacetic acid (TCA) and EDTA were purchased from 
Saarchem (Krugersdorp, South Africa). BHT was dissolved in absolute 
ethanol, while all the other chemicals were dissolved in Milli-Q water. Stock 
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solutions of known concentrations of QUIN, KCN and phenytoin were 
prepared in Milli-Q water. All solutions were prepared fresh on the day of 
the experiments.  
 
4.2.2.  ANIMALS 
 
Animals were kept as described in section 2.2.2.2. 
 
4.2.3.  BRAIN REMOVAL 
 
Rats were sacrificed by neck fracture and decapitated. The brain was 
handled as described in section 2.2.2.5. 
 
4.2.3.1.   Preparation of brain homogenate 
 
On the morning of the experiment, following removal, the whole brains were 
weighed and homogenised in a Teflon® coated glass homogeniser for 60 
seconds on ice. A 10% w/v homogenate was produced with 0.1 M PBS at a 
pH of 7.4. 
 
4.2.4.  PREPARATION OF STANDARD CURVE 
 
1,1,3,3-Tetramethoxypropane was used as a standard. A series of reaction 
tubes, each containing appropriate aliquots of water and standard solution 
were prepared with Milli-Q water to a final volume of 1 ml. A calibration 
curve was generated by measuring the absorbance at concentration intervals 
of 2 nmol. The absorbance was read at 532 nm using a Varian Cary 500 
Scan UV-VIS NIR Spectrophotometer (EL 99053199) and plotted against 
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the molar equivalent weight of MDA in the complex assayed (see appendix 
2). 
 
4.3.   EXPERIMENT 1 
In vitro incubation of rat brain homogenate with the 
Glutamate receptor agonist, QUIN, with varying 
concentrations of phenytoin. 
 
4.3.1.   METHODS 
 
Whole rat brain homogenate was prepared as explained in section 4.2.3.1. A 
modified method of the TBA assay as described by Ottino (Ottino, P. 1996) 
was used to estimate lipid peroxidation.  
 
Whole rat brain homogenate 10% w/v (0.5 ml) containing varying 
concentrations of phenytoin (0–1.25 mM) was incubated with 0.5mM 
QUIN, both dissolved in Milli-Q water, in a shaking water bath for 1 hour at 
37oC. At the end of the incubation, 0.5ml BHT (0.5 g/L in absolute ethanol) 
and 1 ml 25% TCA in Milli-Q water were added to the mixture to stop the 
reaction. The samples were centrifuged at 2000 x g for 20 minutes at 4oC to 
remove insoluble proteins. Following centrifugation, 2 ml of protein-free 
supernatant was removed from each tube, and a 0.5 ml aliquot of 0.33% 
TBA in Milli-Q water was added to this fraction. The concentration range of 
phenytoin used in this experiment was 0–1.25 mM. 
 
All tubes were heated for an hour at 95oC in a water bath. After cooling, the 
TBA-MDA complexes were extracted by vortexing the contents with 2 ml of 
butan-1-ol, to optimise partitioning of the chromogen into the organic upper 
layer. The tubes were then centrifuged again at 2000 x g for 5 minutes to 
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allow complete separation of the two immiscible solvents. The absorbance 
of the top layer was then read at 532 nm in plastic cuvettes having a path 
length of 1 cm and MDA levels were determined from the standard curve 
generated from 1,1,3,3-tetramethoxypropane. Final results were expressed as 
nmoles MDA per mg wet tissue. The incubation mixtures did not contain 
any ethanol or other solvents. 
 
4.3.2.  STATISTICAL ANALYSIS 
 
All data are represented as mean±SD. Statistical analysis was performed 
using a one way analysis of variance (ANOVA) followed by the Student– 
Newman–Keuls multiple range test. Values were accepted as being 
statistically significantly different if a P value was < 0.05. 
 
4.3.3. RESULTS 
 
The results clearly demonstrate that exposure of the whole rat brain 
homogenate to QUIN increased MDA production. This can be noted in 
Figure 4.1, QUIN (0.5 mM) significantly increased lipid peroxidation 
compared to the control. From Figure 4.1, phenytoin at any of the 
concentrations used did not result in an overall decline in MDA production.  
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Figure 4.1. Effect of increasing levels of phenytoin (0 – 1.25 mM) on 0.5 
mM QUIN induced lipid peroxidation in whole rat brain homogenate. The 
height of the columns shows the amount of MDA production per mg of wet 
tissue. The incubation time was 60 min. Each bar represents the mean ± SD 
(n=6); Student Newman Keuls multiple range test. 
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4.3.4.  DISCUSSION 
 
The significance of free radical generation is currently the subject of much 
research in the pathophysiology of many neurodegenerative disorders. 
Neurotoxins, including QUIN (Southgate and Daya. 1999) induce 
neurodegeneration by free radical mechanisms in live neurons. QUIN 
(0.5mM) has a significant outcome on MDA production. These results are 
parallel to those of Rios and Santamaria (1991) who found that QUIN is a 
potent lipid peroxidant in rat brain homogenate.  QUIN causes lipid 
peroxidation in a dose-dependent manner. The reason for this is not clear, 
but it is possible that QUIN is acting as a pro-oxidant, thus initiating lipid 
peroxidation. 
 
This study shows that the antiepileptic drug used, phenytoin, does not reduce 
QUIN induced lipid peroxidation. The protective effect of neuroprotectants 
is likely to be attributable, at least in part, to their direct free radical 
scavenging properties (Reiter, 1998). Moreover, other mechanisms such as 
stabilisation of cell membranes, (allowing them to resist free radical 
processes more efficiently) (Garcia et al. 1998) and the stimulation of 
antioxidative enzymes that renders toxic free radicals to non-toxic products 
(Barlow-Walden et al. 1995, Reiter. 1998) should play a role in decreasing 
QUIN induced lipid peroxidation. Phenytoin clearly does not possess these 
properties when used in whole rat brain homogenate. It is also possible that, 
because brain homogenate contains a big proportion of dead cells and that 
phenytoin can only protect from damage due to NMDA receptor mediated 
toxicity as discussed in chapter 1, the drug was not able to prevent damage. 
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4.4.   EXPERIMENT 2 
Effects of phenytoin on iron induced lipid peroxidation in 
whole rat brain homogenate 
4.4.1.       INTRODUCTION 
The role of iron on free radical and lipid peroxidation reactions has been 
studied extensively and its role in this regard is widely accepted (Fahn et al, 
1992). Transition metals promote lipid peroxidation in two ways. These can 
catalyse the formation of oxygen free radical species capable of initiating 
lipid peroxidation. In addition, they can also favour the decomposition of 
preformed lipid peroxides to propagate lipid peroxidation (Rikans et al, 
1997). 
 
In this study, iron was used to generate free radicals and the effects of 
phenytoin on iron-induced lipid peroxidation in whole rat brain homogenate 
were investigated.  
4.4.1.   MATERIALS AND METHODS 
Rat whole brain homogenate was prepared as explained in section 4.2.3.1. A 
modified method of the TBA assay as described by Ottino (1996) was used 
to determine the extent of lipid peroxidation lipid peroxidation.  
 
0.5 ml of a 10 % w/v whole rat brain homogenate containing the following 
reagents, iron sulphate (5 mM), EDTA (100 µM), H2O2 (2.8 mM), phenytoin 
(0.0-1.50 mM), and ascorbate (100 µM), were added in the sequence stated.  
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The reaction mixture was incubated in an oscillating water bath for 1 hour at 
37°C. The experiment was continued as outlined earlier in Section 4.3.1. 
Final results are expressed as nmoles of MDA per mg wet tissue. 
4.4.3.  STATISTICAL ANALYSIS 
Refer to section 4.3.2. 
4.4.4.   RESULTS 
Exposure of whole rat brain homogenate to various concentrations (0–1.50 
mM) of phenytoin decreased iron-induced lipid peroxidation significantly as 
compared to the control (Figure 4.2.). Iron II at a concentration of 5 mM 
produced a significant increase of about 700% in MDA production. 
Phenytoin caused a dose-related reduction in lipid peroxidation. A 500% 
reduction of iron-induced lipid peroxidation was achieved with a 1.50 mM 
phenytoin as shown in Figure 4.2. 
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4.4.5.    DISCUSSION 
A significant dose related reduction of iron II induced MDA production by 
the antiepileptic agent, phenytoin was observed whereas this behaviour was 
not seen for QUIN-induced lipid peroxidation. It is possible that Phenytoin 
acts by scavenging the hydroxyl radicals generated, chelating or complexing 
with the iron (II) or oxidising it to iron (III), such that iron (II) becomes 
unavailable hydroxyl radicals via the Fenton type reactions as mentioned 
earlier. 
It had been suggested that phenytoin binds to metallic ions and forms 
complexes. Because phenytoin is not a good free radical quencher as found 
in the last chapter and with QUIN-induced lipid peroxidation, it can be 
inferred that a possible interaction between the drug and iron might be 
occurring and thereby preventing the generation of the potent damage 
causing hydroxyl radicals. Hence this interaction with iron might be an 
additional mechanism by which the drug confers protection when used 
during ischaemic episodes, strokes and trauma, during which it has been 
reported that an increase in free iron concentration occurs in the CNS. 
 
This concept of phenytoin interacting with metals, especially iron (II) will be 
further investigated in the next chapter in an attempt to shed more light on 
this interaction. 
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CHAPTER 5 
 
IRON BINDING STUDIES 
 
5.1 INTRODUCTION 
 
The iron contained in the body is absorbed from the gut, and originates from 
the diet that is consumed. Most body iron is contained in haemoglobin, with 
smaller amounts in myoglobin, co-factors of various enzymes and the 
transport protein transferrin. Excess iron is stored as ferritin, which can hold 
up to 45 000 ions of iron (Halliwell & Gutteridge, 1989). Transferrin enters 
the cytoplasm in a vacuole, which is acidified to release the iron. The 
transferrin is then ejected leaving behind non-protein-bound iron. This can 
be used in the synthesis of iron proteins. Cells use this process to minimize 
the intracellular iron concentration (Halliwell & Gutteridge, 1989). 
Oxidative processes can provide the iron required for Fenton chemistry by 
mobilizing iron from ferritin or by degradation of haem proteins. Studies 
have reported that the formation of the very reactive hydroxyl radical in vivo 
may increase during tissue injury.  
 
This is significantly important in the brain since CSF has no considerable 
iron-binding capacity, and mechanical disruption of the brain releases iron 
that can stimulate radical reactions such as lipid peroxidation. Consequently, 
brain homogenate, for example, is known to undergo lipid peroxidation at a 
much faster rate than isolated intact brain (Halliwell & Gutteridge, 1989). 
Another important aspect to consider is that free radicals are able to initiate 
lipid-destroying chain reactions (Southgate & Daya, 1999), particularly in 
the brain, because it contains large amounts of polyunsaturated lipids. Many 
neurological disorders are associated with iron overload (Halliwell B., 
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1992). These include asymptomatic deposition of iron in the basal ganglia 
(Berg D et al., 2000), psychiatric diseases (Cutler P., 1994), dementia, ataxia 
and myoclonic jerks. 
 
Moreover, Halliwell & Gutteridge (1989), have reported that iron (II) 
complexes react with lipid peroxide to generate iron (III) and an alkoxyl 
radical. They also noted that iron (II) complexes stimulate membrane 
peroxidation to a greater extent as compared to iron (III). 
 
Iron is a grey metal with the outer electronic configuration 3d64s2. The metal 
is found amongst the d-block elements of the periodic table. Iron exhibits 
several oxidation states in its compounds, of which the two most important 
ones are; 
 
• Iron (II) electronic configuration 3d6 
• Iron (III) electronic configuration 3d5 
 
Iron (III) is more stable than iron (II) since each of its five 3d-orbitals is 
singly occupied by an electron. The iron (II) ion, Fe2+, is hydrated in 
aqueous solution. It exists as the pale green hexa-aquairon (II) complex ion 
[Fe(H2O)6]3+. The ion is stable in acidic conditions and readily forms 
hydrated iron (III) ion in neutral or alkaline solution. 
 
One of the most important chemical properties of d-block elements is their 
ability to form complex ions. A complex ion is formed when one or more 
molecules or negatively charged ions become attached to a central atom. The 
molecule or negative ion that becomes attached is called a ligand. Some 
ligands are able to form ring structures with central atoms. This property is 
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referred to as chelation and the resulting compounds known as chelate 
compounds (Freemantle, M., 1987). 
 
The additional protective mechanism conferred by phenytoin during iron-
induced lipid peroxidation was investigated by gauging the interaction of 
phenytoin with iron using the following techniques listed below: 
 
• UV/VIS spectrophotometry 
• Electrochemistry 
• IR analysis  
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5.2 MATERIALS AND METHODS 
 
5.2.1.      CHEMICAL REAGENTS 
 
Phenytoin was purchased from Sigma Chemical Co., St. Louis, MO, USA. 
Ferrous sulphate (FeSO4.7H2O) and Ferric chloride (FeCl3) were obtained 
from Merck, Midrand, South Africa. 
 
5.2.2.  PREPARATION OF THE PHENYTOIN-IRON 
COMPLEX 
 
An excess of 4 mM solution of phenytoin (ligand) was added to 1 mM 
solution of ferrous sulphate (central atom) and stirred continuously for 2 
hours. Both compounds were dissolved in deaereated Milli-Q water so that 
iron (II) stays in its reduced form for a longer period as dissolved oxygen 
favours the conversion of iron (II) to the oxidised state, iron (III). The pH of 
the reacting solution was found to be 7.9. No buffer was used in the 
preparation. On addition of the ligand, the pale green colour of the metal ion 
solution changed to clear deeper green solution. Immediately afterwards, 
(approximately 2 seconds), a reddish brown precipitate was formed and this 
was believed to be the complex. The same procedure was used to synthesise 
the iron (III)- phenytoin complex using FeCl3. 
 
The precipitate formed was filtered under vacuum and rinsed with an excess 
of Milli-Q water. It was then dried in an oven at 400C for 12 hours to remove 
water. 
 
A dry weight of 1.5 g of the phenytoin-metal complexes was obtained for 
both iron (II) and iron (III) ions. 
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5.2.3. UV/VIS analysis 
 
Ultraviolet radiation normally excites electrons from one molecular orbital 
to another. An example is when an electron, such as a pi electron of a 
carbon-carbon double bond, after absorbing a particular quantity of energy, 
is promoted from the highest occupied molecular orbital to the lowest 
unoccupied molecular orbital. As a result, by irradiating UV light of 
continuously changing wavelength, a UV spectrum unique to an organic 
compound is produced. Moreover if that particular organic compound 
interacts chemically with any other compounds or metallic ions, a change in 
the absorption spectrum is expected. 
 
The UV/Visible spectra were monitored using a Varian Cary 500 Scan UV-
VIS NIR Spectrophotometer (EL 99053199). Concentrations of metal were 
kept constant (1 mM) and spectra measured on addition of excess phenytoin 
(2 mM) solution. Spectra were scanned at 30 second time intervals, time 
starting immediately after the addition of the phenytoin solution to the metal, 
iron (II), solution. This was carried out in a quartz cuvette of 1 cm path-
length over a wavelength range of 190-800 nm. The experiment was carried 
out until no further shifting of peaks occurred and stopped 30 seconds after 
the precipitate became visible on the wall of the cuvette. All solutions were 
freshly prepared in deaerated Milli-Q water and glassware were treated with 
a dilute solution of nitric acid before usage. The experiment was repeated 
using iron (III) instead of iron (II). 
5.2.4.. INFRARED SPECTROSCOPY 
 
IR analysis simplistically determines the functional group of compounds. 
The full interpretation of an IR spectrum is difficult because most organic 
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molecules are so large that there are dozens or hundreds of different possible 
bond stretching and bending motions. Thus, an IR spectrum contains dozens 
or hundreds of absorptions. This complexity is valuable, since the spectrum 
serves as a unique fingerprint of a specific compound.  
 
Essentially IR spectroscopy involves the interaction of a molecule with 
electromagnetic radiation. When an organic molecule is irradiated with IR 
light, the molecule absorbs particular frequencies of light. The frequencies 
absorbed correspond to the amounts of energy needed to increase the 
amplitude of specific molecular vibrations such as bond stretching and 
bending. Every functional group has a characteristic set of infrared 
absorptions. 
 
In this experiment, the IR spectra of the phenytoin-metal complex formed 
and phenytoin were produced using potassium bromide pellets. 
 
Care was taken to ensure that no air was trapped between the disks, before 
samples were scanned from 1000 cm-1 to 4000 cm-1. IR spectra of phenytoin 
were also run for comparison. Blank IR spectra were run in air. 
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5.2.5.  ELECTROCHEMISTRY 
 
Electrochemistry offers a valuable tool in gauging metal ligand interactions. 
Cyclic voltammetry, used to characterise species in solution and adsorptive 
stripping Voltammetry, a tool to examine metal-ligand complex formation at 
an electrode, were used in this work. A three-electrode system was used 
comprising the working electrode, a reference electrode and an auxiliary 
electrode. These techniques are discussed in more detail below. 
 
5.2.5.1. The Electrodes 
 
The working electrode is the electrode where electron transfer reactions 
occur. The most utilised working electrodes are those of metallic origins 
such as mercury, platinum and gold, which offer fast electron transfer rates. 
A glassy carbon electrode (GCE) was used in this thesis. GCEs comprise of 
a material that has excellent mechanical and electrical properties, a wide 
potential window, is chemically inert and exhibit reproducible performance.  
 
In this experiment the silver/silver chloride electrode was used as the 
reference electrode against which all potentials are referenced. It consists of 
a silver wire anodised with silver chloride. 
 
Usually constructed of an inert metal such as platinum in the form of a wire, 
loop or foil, the auxiliary electrode completes the circuit. 
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5.2.5.2. Cyclic / Adsorptive Stripping Voltammetry 
 
In Cyclic Voltammetry the underlying theory is that electroactive analytes in 
solution produce characteristic redox patterns when a potential range is 
scanned. Consequently, any changes in potentials or the intensity of current 
response are an indication of new species in solution. Cyclic 
Voltammograms (CV) were obtained with the Bio Analytical Systems 
(BAS) CV-50W voltammetric analyser using a BAS C2 cell stand to 
maintain constant atmosphere. A 3mm diameter glassy carbon electrode 
(GCE) was employed as a working electrode for voltammetric experiments. 
 
A silver/silver chloride ([AgCl = 3 M]) and a platinum wire were employed 
as reference and auxiliary electrodes, respectively. Between scans, the GCE 
was cleaned by polishing with alumina on a Buehler pad, immersion in a 
dilute nitric acid and rinsed with deionised water and the buffer solution. 
 
For cyclic voltammetric experiments, appropriate concentrations of 
phenytoin in buffer were introduced into a glass cell and degassed for 5 min 
with nitrogen before scanning a potential window. In contrast, in organic 
solutions, a silver wire was used instead of the silver/silver chloride 
reference electrode as a pseudo reference electrode. In these instances 
ferrocene was used as an internal standard. Potentials were referenced to 
ferrocene by subtracting E1/2 ferrocene from potentials measured at the Ag 
wire. The E1/2 of ferrocene has been determined in DMSO to be 0.50 V vs. a 
saturated calomel electrode. Potentials vs. ferrocene were thus referenced to 
the saturated calomel electrode by adding 0.05 V to these values. Potential 
values were then referenced to Ag/AgCl, 3M KCl by adding 0.05 V to these 
values. All potential values reported are vs. Ag/AgCl. 
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Adsorptive Stripping Voltammetry is a technique used to examine metal-
ligand complex formation at an electrode. It is dependent on the tendency of 
analytes to preconcentrate at the surface of a working electrode. The 
introduction of a ligand into a metal solution causes an increase in the pre-
concentration of the metal at the electrode if it forms a metal-ligand 
complex. The formation of this complex causes an increase in the current 
response due to metal reduction. A shift in the reduction potential indicates 
that a new species is being reduced. 
 
For adsorptive stripping experiments appropriate concentrations of the metal 
(Fe2+ or Fe3+) and of the ligand (phenytoin) were introduced into an 
electrochemical cell. The solution was then deaerated with nitrogen for 5 
min, after which a flow of nitrogen was maintained over the solution 
throughout the experiment.  
 
Optimum deposition potential for iron (II) and iron (III) were identified and 
applied for 60 s to effect the formation and adsorption of the metal and 
ligand species onto the glassy carbon electrode. The voltammograms were 
then scanned in the negative direction from the deposition potential to 500 
mV beyond the reduction potential of the metal species at a scan rate of 0.1 
V s-1 to strip the adsorbed metal-ligand species from the electrode. During 
the stripping step, current response due to the reduction of the metal–ligand 
species were measured as a function of potential. 
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5.3.   RESULTS 
 
5.3.1.  UV/ VIS analysis  
 
Table 5.1. The major peaks observed for Fe2+ and phenytoin 
 
Peak Wavelength (nm) 
Phenytoin only 200.8 
Fe2+ + Phenytoin 
(T= 0.0 mins) 
210.1 
Fe2+ + Phenytoin 
(T=  0.5 mins)  
211.0 
Fe2+ + Phenytoin 
(T= 1.0 mins)  
211.0 
 
 
The major band observed for phenytoin was at 200.8 nm. This band shifted 
to 210.1 nm immediately after the addition of the ligand to the metal ion 
solution without shift in peak height. No new bands were observed. The 
reaction was stopped after 1.0 minute when no further changes in 
absorbance values and in band shifting occurred and precipitation of the 
metal-ligand complex occurred.  
 
In addition to the changes in peak wavelengths of phenytoin, a distinct 
colour change was observed from the pale green colour of the Fe (II) 
solution to a deeper green colour immediately after the addition of 
phenytoin. Following this, the colour quickly changed to a reddish brown 
clear solution and subsequently, precipitation of what was believed to be the 
end product of a ligand-metal interaction occurred. 
 
When the UV/VIS analysis was repeated using FeCl3 instead of FeSO4 with 
phenytoin in the same aqueous environment the following results were 
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obtained and are shown in table 5.2. below. This experiment also gave a 
shift of the phenytoin peak at 200.8 nm to 210.9 nm after a 1 minute time 
period. 
 
Table 5.2. The major peaks observed for Fe3+ and phenytoin 
 
Peak Wavelength (nm) 
Phenytoin only 200.8 
Fe3+ + Phenytoin  
(T= 0.0 mins) 
209.9 
Fe3+ + Phenytoin 
(T=  0.5 mins)  
210.9 
Fe3+ + Phenytoin 
(T= 1.0 mins)  
210.9 
 
 
5.3.3. ELECTROCHEMICAL STUDIES 
 
All potentials are referenced against the Ag/AgCl reference electrode, unless 
otherwise stated.  
 
Figure 5.1. shows the CV for phenytoin alone in solution in pH 4.25 sodium 
acetate buffer. One quasi-reversible couple with a cathodic potential of –
0.65 V and an anodic potential of 0.75 V was observed. The halfwave 
potential (E1/2) was equal to 0.05 V 
 
Adsorptive stripping voltammograms (ASV) of studies of Fe2+ and 
phenytoin at pH 4 are shown in Figure 5.2. Figure 5.2 (a) shows the ASV for 
3 x 10-5 M Fe2+, with a reduction potential of –0.28 V.  In the presence of 
increasing concentrations of phenytoin, this peak increases and shifts to less 
negative potentials of –0.27 V as shown for 3 x 10-5 M phenytoin in Figure 
5.2 (b) and 9 x 10-5 M phenytoin in Figure 5.2 (c).  
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ASV for studies of Fe3+ and phenytoin at pH 4.25 (sodium acetate buffer), 
are shown in Figure 5.3. Figure 5.3 (a) shows the ASV for 3 x 10-5 M Fe3+, 
with a reduction potential of –0.65V. Increasing concentrations of phenytoin 
reduces the current response observed for Fe2+ with no shifts in potential, as 
shown in Figure 5.3.(b) to 5.3.(d) for 3 x 10-5 M, 9 x 10-5 M and 1.2 x 10-4 M 
phenytoin respectively.  
 
CV of the iron-phenytoin complexes isolated were conducted using dimethyl 
sulphoxide (DMSO) as a solvent and tetraethylammonium phosphate 
(TEAP) as the electrolyte and compared to the CV of phenytoin alone. 
Based on the quoted E1/2 values of ferrocene in DMSO, all potentials were 
recalculated and final potentials reported against Ag/AgCl. Figure 5.4 (a) 
shows the CV for phenytoin alone in solution with a quasi-reversible couple. 
A cathodic peak potential of –0.57 V and anodic potential of –0.38 V was 
observed. Figure 5.4 (b) shows the CV for a phenytoin-Fe complex. Here, 
the cathodic peak potential is observed at –0.53 V with an anodic peak 
potential of –0.25 V. The cathodic return peak potential in Figure 5.4 (b) is 
slightly less negative than that of phenytoin alone, while the anodic peak 
potential is slightly more negative than that of phenytoin alone. These subtle 
shifts indicate an altered cyclic voltammetric profile for the phenytoin-iron 
complex. 
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Figure 5.1. CV for phenytoin alone in solution in pH 4.25 sodium acetate 
buffer 
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Figure 5.4. CV of phenytoin and the iron-phenytoin complexes in DMSO 
and TEAP as electrolyte. 
 
5.3.2.  INFRARED SPECTROSCOPY 
 
The IR spectroscopic graphs for phenytoin, Fe2+-phenytoin and Fe3+-
phenytoin (Figures 5.5, 5.6 and 5.7, respectively) indicate a shift in the 
major peak obtained at 3312.9 cm-1. This peak represents the NH group 
present on the phenytoin molecule. In the Fe2+-phenytoin and Fe3+-phenytoin 
(Figures 5.6 and 5.7, respectively), the signal appearing due to this NH 
group occurring at 3312.9 cm-1 in the phenytoin molecule only, is split and 
shifted to 3198.4 cm-1 and 3267.1 cm-1.  
 
In addition, comparing the carbonyl peak in the infrared spectrums of 
phenytoin only and the metal-ligand product, a shift from 1596.1 cm-1 and 
1687.6 cm-1 to 1714.2 and 1771.4 cm-1 respectively was noticed (Figures 
5.5, 5.6 and 5.7). No important splitting was observed after interaction. 
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Figure 5.5. Infrared spectrum of phenytoin 
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Figure 5.6. Infrared spectrum of iron (II) –phenytoin interaction product 
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Figure 5.7. Infrared spectrum of iron (III) –phenytoin interaction product 
 
5.4.  DISCUSSION 
 
5.4.1. UV/VIS analysis 
 
Table 5.1.and 5.2. shows the shift in the major bands observed. The shift 
observed indicates that phenytoin is able to interfere with these ions to form 
a new entity that absorbs energy at these new wavelengths. This suggests a 
possible interaction between Fe2+ and Fe3+ with phenytoin in an aqueous 
environment.  
 
In addition, the changes in colour observed in the cuvettes, permits 
speculation that phenytoin might be firstly reacting with the pale green iron 
(II) solution and oxidising it to the iron (III) state that has a characteristic 
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reddish brown colour followed by precipitation of the reaction product. In 
addition, apart from the colour changes that were not observed with iron (III) 
as the latter was already in its oxidised form, the UV/VIS spectrum had a 
very similar profile to that when Fe2+ was allowed to react with phenytoin. 
This allowed speculation that phenytoin maintains iron in its iron (III) state 
when bound. 
 
From this experiment, it can be postulated that phenytoin interacts with Fe 
(II) and Fe (III) ions in a different manner but the resulting product of the 
reaction can be said to be identical. The next two sections will deal with the 
Infrared spectroscopy and electrochemical techniques to confirm and shed 
more light on this interaction. 
 
5.4.2. Electrochemical studies 
 
From the ASV technique used to study the interaction of Fe2+ and phenytoin 
at pH 4, the increase in current response observed for the reduction of Fe2+ 
in the presence of phenytoin indicates a metal-ligand interaction between 
these species in solution. The shift to less negative potentials indicates that 
the metal-ligand species is easier to reduce than the metal alone. This 
indicates a weak metal-ligand interaction between Fe2+ and phenytoin. 
 
In addition, the decrease in current response with the studies for Fe3+ and 
phenytoin in Figure 5.3 may indicate that the electrode is saturated, but this 
is not likely at such low metal and ligand concentrations, or it may indicate 
that the Fe3+ is bound in a form which is not easily reduced by the ligand. 
The latter may be the case as this is the response observed for such studies 
with strong ligands. However, the lack of a potential shift does not support 
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this theory and therefore the interaction of Fe3+ and phenytoin in this study is 
not conclusive but warrants further examination through other solution phase 
techniques. 
 
5.4.3. Infrared Spectroscopy 
 
From the results obtained it can be noted that splitting and shifting of peaks 
occurred in the region representing the NH functional group. This suggests 
that coordination might be taking place at the NH functional group or that 
there has been a change in the chemical environment of the functional group 
after interacting with the metal ions. 
 
Moreover the spectra obtained with the iron (II)–phenytoin and iron (III)- 
phenytoin were not different which suggests that phenytoin is bound to iron 
(III). This further suggests that phenytoin oxidises iron (II) to iron (III) 
before binding of the ligand to the metal occurs. 
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CHAPTER 6 
 
ORGAN CULTURE STUDIES: THE EFFECT OF 
PHENYTOIN ADMINISTRATION ON RAT PINEAL 
INDOLE METABOLISM 
 
6.1. INTRODUCTION 
 
Organ culture originated in the Strangeways laboratory more than 60 years 
ago (Strangeways & Fell, 1926) and the method was used chiefly for the 
culture of organ rudiments. With various modifications of apparatus and 
techniques being used for organ culture, it is now possible to isolate and 
culture specific organs so as to keep a number of fully differentiated organs 
alive in vitro without growth or differentiation. Thus, the organ culture 
system allows pharmacological and biochemical manipulations of different 
organs without the complicating influences of in vivo milieu.  
 
The choice of organ was the pineal gland located in the brain. The pineal 
gland is recognized as a fully functional organ that is responsible for the 
synthesis of indoleamines. Of particular interest is the pineal hormone, 
melatonin that has been shown to be an effective free radical scavenger 
(Reiter et al, 1995). 
 
In this study, the effect of phenytoin on rat pineal indole metabolism was 
assessed.  
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incubation period, the pineal glands take up the radioactive serotonin and 
synthesize [14C] indoles. Approximately 98% of the [14C] indole products 
are secreted into the culture medium, apparently by passive diffusion (Klein 
& Rowe, 1970; Morton, 1990). The relative amount of medium is 
considered a good reflection of pineal indole biosynthesis. After the 
incubation period, an aliquot of the culture medium is analysed for its 
content of radioactive serotonin metabolites by using TLC and 
scintillometry. 
 
6.2. MATERIALS AND METHODS 
 
6.2.1. ANIMALS 
 
Male Wistar rats weighing 250g -300g were used in this experiment. These 
were randomly assembled into 2 groups of 5 and maintained as described in 
section 2.2.2.2. 10 rats were used and from each the pineal gland was 
removed and cultured. The control group received the drug vehicle only and 
the test group was treated with phenytoin. The treatment regimen used can 
be viewed in Table 6.1 below. 
 
Table 6.1. Treatment regimen for each group of animals 
 
GROUP Received intra- peritoneally for 7 days  
CONTROL PBS 0.1 mM 
 
PHENYTOIN Phenytoin (20 mg/kg) in PBS 
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6.2.2. MATERIALS 
 
(14C) serotonin (specific activity 57.0 mCi/ml) was obtained from 
Amersham International, England. The BGJb culture medium was purchased 
from Gibco, Europe and supplemented with the antibiotics streptomycin and 
benzyl penicillin (Hoechst, South Africa). The aluminium TLC plates coated 
with silica gel 60, Type F254 (0.25 mm), were purchased from Merck, 
Darmstadt, Germany. Beckman ready-Sol multipurpose liquid scintillation 
fluid was purchased from Beckman RIIC Ltd, Scotland. Phenytoin and the 
indole standards MT, HA, HL, MA, ML, aMT and aHT were purchased 
from Sigma Chemical Co, St. Louis, USA. All other materials used were 
obtained from local sources and were of the highest quality available. 
  
6.2.2.1.  Composition of BGJb medium used for organ 
culture studies (Fitton-Jackson modification) 
 
Table 6.2. Composition of BGJb medium used for organ culture studies 
(Fitton-Jackson modification) Mean tonicity = 390 milliosmoles 
 
COMPONENTS     CONCENTRATION (mg/L) 
Inorganic Salts 
Dihydrogen sodium ortho phosphate     90.00 
Magnesium sulphate 7H2O      200.00 
Potassium chloride       400.00 
Potassium dihydrogen phosphate     160.00 
Sodium bicarbonate       3 500.00 
Sodium chloride        5 300.00 
Amino Acids 
L – Alanine         250.00 
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L – Arginine        175.00 
L – Aspartic acid        150.00 
L- Cysteine HCl        90.00 
Glycine         800.00 
L – Histidine        150.00 
L – Isoleucine        30.00 
L – Leucine         50.00 
L –Lysine         240.00 
L – Methionine        50.00 
L – Phenylalanine        50.00 
L – Proline         400.00 
L – Serine         200.00 
L – Threonine        75.00 
L – Tryptophane        40.00 
D, L – Valine        65.00 
Vitamins 
Alpha tocopherol phosphate      1.00 
Ascorbic acid        50.00 
Biotin         0.20 
Calcium pantothenate       0.20 
Choline chloride        50.00 
Folic acid         0.20 
Inositol         0.20 
Nicotinamide        20.00 
Para aminobenzoic acid       2.00 
Pyridoxal phosphate       0.20 
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Riboflavin         0.20 
Thiamine hydrochloride       4.00 
Vitamin B12         0.04 
Supplements 
L – Glutamine        200  
Streptomycin sulphate        0.1 
Amphotericin B        2.5 µg/ml 
Benzyl Pennicillin        100 units/ml
Other components 
Calcium lactate        555.00 
Glucose         10 000.00 
Phenol red         20.00 
Sodium acetate        50.00 
 
6.2.2.2. Organ culture method 
 
The pineal glands were placed individually into sterile 75 x 10mm Kimble 
tubes containing 52 µl of BGJ culture medium. 8 µl of (14C) serotonin 
(specific activity 57.0 mCi/ml) was added to each tube. The culture vessels 
were placed in sterile tubes and before being sealed were gassed with 
carbogen. The tubes were then placed in the dark in a Forma scientific 
model 3028 incubator at 37°C for 24 hours. 
 
After the incubation period of 24 hours the reaction was stopped by the 
removal of the pineal glands from the culture vessels. A 20 µl aliquot of the 
culture medium from each of the ten tubes was spotted on different TLC 
plates cut 10 x 10 cm. Following this 10 µl of standards of all the pineal 
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After the incubation period of 24 hours the reaction was stopped by the 
removal of the pineal glands from the culture vessels. A 20 µl aliquot of the 
culture medium from each of the ten tubes was spotted on different TLC 
plates cut 10 x 10 cm. Following this 10 µl of standards of all the pineal 
serotonin metabolites were spotted on top of the culture medium spot. All 
spotting was carried out under low intensity light to prevent photo-oxidation 
of the indoleamines.  
 
The solution containing the standards was made up as follows: 
 
1 mg of each of the 8 standards used were pooled and dissolved 
in a test tube containing 2.5ml of 95 % ethanol. 2.5ml of 1% 
ascorbic acid in 0.1M HCl was added. A gentle stream of 
nitrogen was used to dry the spots which were not greater 
them 0.5cm. The purpose of the nitrogen was to prevent 
atmospheric oxidation of the metabolites. 
 
The plates were then placed in a TLC tank containing chloroform: methanol: 
glacial acetic acid (97:7:1) as mobile phase. The plates were developed 
twice in one direction, and allowed to develop until the solvent front had 
migrated approximately 9 cm. The plates were allowed to dry and then 
placed at right angles to the first direction of development, to develop once 
in ethyl acetate. The plates were allowed to dry and then placed under UV 
light to visualise the separation of the indoles. A typical trace of a TLC plate 
is seen in Figure 6.1. The spots were cut and individually placed into 
scintillation vials to which 1 ml of absolute ethanol was added, vortexed and 
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allowed to stand for 1 hour. After this time 3 ml of beckmans Ready-Sol 
scintillation fluid was added and vortexed again for 30 seconds. 
 
Finally all the vials were left for 24 hours before the radioactivity of each 
metabolite was measured using a Beckman LS 2800 scintillation counter. 
 
6.2.2.3.      Statistical analysis 
 
The results obtained were analysed using a One Way Analysis of Variance 
(ANOVA), followed by a Student Newman-Keuls Multiple Range test. * P≤ 
0.05, ** p≤ 0.01, which indicates that the results obtained are significant. 
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6.3.               RESULTS 
 
MOBILE PHASE A [x2]: 
 
Chloroform 93 
Methanol     7 
Glacial acetic acid 1 
 
 
 
 
 
 
MOBILE PHASE B [x1]: 
 
 
Ethyl acetate 
 
 
 
 
   
      
 
 
 
   MEL   
                                                              MTOH                     
                                                                                MIAA 
       
    
            
   NAS              HTOH 
                                                                          HIAA 
      
 5HT 
   5MT 
 
 
 
 
 
 
 
 
 
 
 
   5HT= Serotonin 
                   5MT= 5-Methoxytryptamine 
                   NAS= N-acetyl serotonin 
                   MEL= Melatonin 
  MTOH= Methoxytryptophol 
                   MIAA= Methoxyindoleacetic acid 
  HTOH= Hydroxytryptophol 
  HIAA= Hydroxyindoleacetic acid   
 
Figure 6.1. Tracing of a typical bi-dimensional thin layer chromatographic 
separation of pineal indole compounds  
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Excellent separation of the indoles was achieved and the different 
metabolites separated can be seen in the typical bi-dimensional thin layer 
chromatogram from Figure 6.1.  
 
Results are an average of five estimations and expressed as CPM/10 
µl/pineal gland (mean ± SD) for each indole. The background counts were 
negligible.  
 
The rats treated with phenytoin (Table 6.3) showed a statistical difference 
only for the NAS, MIAA and the MTOH levels. In addition, a non-
significant decrease in MEL was observed in the phenytoin treated rats. 
 
Table 6.3. Concentrations of indoles in CPM/10µl/pineal (n=5) 
 
Pineal 
Metabolites 
Control 
CPM/10 µl/pineal     
  Mean ± SD 
Phenytoin 
CPM/10 µl/pineal     
  Mean ± SD 
N-acetyl serotonin 
(NAS) 
 1258 ±254  2055±636 ** 
5-Hydroxyindoleacetic 
acid (HIAA) 
 35984±5385 36378±3574 
5-Hydroxytryptophol 
(HTOH) 
 9980±1697 10284±663 
Melatonin  
(MEL) 
 705±94  532±160 
5-Methoxyindole acetic 
acid (MIAA) 
 1840±272 1077±154** 
5-Methoxytryptophol 
(MTOH) 
 1888±659 1692±658* 
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6.4.          DISCUSSION 
The serotonin taken up by the pineal gland further can undergo three 
different metabolic pathways to synthesise the pineal indoles. This can be 
seen in Figure 1.10. from section 1.5.4. There are numerous enzymes, co-
enzymes and cofactors that take part in these reactions. 
 
Serotonin that is taken up by the pineal is acetylated to N-acetylserotonin by 
the enzyme serotonin N-acetyltransferase (NAT), with acetyl coenzyme A 
being the acetyl donor (Weissbach et al., 1960). N-actylserotonin can further 
be used by the pineal as a precursor of melatonin (Klein et al., 1971). This 
conversion occurs by O-methylation in the 5-position by another enzyme 
hydroxyindole-O-methyltransferase (HIOMT). Moreover serotonin can also 
undergo other reactions such as deamination, oxidation and methoxylation to 
produce the other metabolites such as HIAA, HTOH, MTOH, and 5MT by 
the action of specific enzymes. 
 
From this experiment it is observed that the rat pineal gland was able to 
metabolise (14C) serotonin to the various pineal indoles. From Table 6.3, the 
7 days administration of 20 mg/kg phenytoin did not result in significant 
changes in melatonin synthesis although a lower level of melatonin was 
obtained in the rats treated with phenytoin. 
 
Phenytoin administration reduced MEL synthesis very insignificantly. This 
probably occurs because phenytoin may interfere with the rate of uptake of 
serotonin into the pineal gland. Moreover, in the group treated with 
phenytoin, the amount of NAS was significantly higher than that of the 
control. Because NAS is the precursor of MEL and taking into consideration 
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that the latter is the precursor of melatonin, theoretically more MEL should 
have been synthesised. However this was not the case. This is probably 
because phenytoin might be interacting with the enzyme HIOMT, which is 
responsible for the O-methylation of NAS to form MEL, in some manner 
that may be reducing its activity. 
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CHAPTER 7 
 
SUMMARY OF RESULTS AND CONCLUSIONS 
 
7.1.  CHAPTER 2: Histochemical investigations of quinolinic acid 
induced damage in the hippocampal area of rat brain. 
 
Light microscopy was employed to examine the effects of QUIN-induced neuronal 
damage in the hippocampus of rats after intra-hippocampal injections of 500 nmoles 
QUIN using stereotaxic techniques. The Nissl body of the neurons of the hippocampus 
were stained purple using cresyl violet. The micrographs of QUIN injected rats indicate 
increased neuronal damage in the CA1 and CA3 regions of the rat brain. The cells in 
these two above-mentioned regions appeared rounded and swollen and necrosis of tissue 
could also be noted. In contrast the control slides had cells that were well structured and 
maintained their characteristic pyramidal shapes and integrity with no signs of necrosis. 
At a systemic dose of 20 mg/kg of phenytoin administered intra-peritoneally, the damage 
caused by QUIN was reduced as the cells seem to closely resemble the ones of the 
control where no toxin was present. This shows that the sodium channel blocker, 
phenytoin confers some degree of protection in the hippocampus under the insult of 
QUIN in vivo. QUIN, an excitotoxin, acts on the NMDA receptor where it causes 
overstimulation of the receptor culminating in a cytotoxic effect that consequently leads 
to neuronal cell death. The protection offered by phenytoin is believed to occur because 
of the sodium ion channel blocking property of this drug, resulting in decreased 
excitability of the neurons, thereby preventing the events leading to cell death. 
 
7.2. CHAPTER 3:   Effects of phenytoin on superoxide generation 
in whole rat brain homogenate. 
 
This study examined the effect of phenytoin on superoxide free radical generation in 
whole rat brain homogenate by using the NBT assay. KCN was used to generate 
superoxide radicals by incubating the neurotoxin with brain homogenate in the presence 
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and absence of phenytoin at concentrations ranging from 0 to 1.25 mM. The experiment 
showed that increasing concentrations of KCN (0, 0.25, 0.5, 1mM) increased superoxide 
generation significantly. This increase was not reduced by phenytoin at any of the 
concentrations used. This indicates that phenytoin was neither reducing the rate of 
production nor scavenging the superoxide anions generated by the neurotoxin KCN and 
thus it can be concluded that phenytoin will not be effective in preventing superoxide 
generation after episodes that lead to their generation in the CNS. 
 
7.3. CHAPTER 4:  Effects of phenytoin on quinolinic acid and iron 
(II) induced lipid peroxidation in whole rat brain homogenate. 
 
This study was conducted to examine the effect of phenytoin on MDA levels after 
inducing lipid peroxidation with two known neurotoxins, namely QUIN and iron (II) in 
whole rat brain homogenate. Both neurotoxins induced damage, as a significant increase 
in lipid peroxidation was noted. When the brain homogenate was incubated with QUIN 
as the neurotoxin, phenytoin at any of the employed concentrations (0 to 1.25 mM) did 
not result in a decline in MDA production. QUIN is known to induce lipid peroxidation 
mostly via a free radical mechanism in whole rat brain homogenate, whilst phenytoin did 
not have any significant effect. Hence it can be said that the drug does not interact with 
free radicals to reduce their toxicities but somehow could enhance lipid peroxidation in a 
manner that could involve the formation of a reactive binary complex between phenytoin 
and the existing free radicals. However under the insult of iron (II), the increase in MDA 
levels after lipid peroxidation were significantly lowered by the drug in a dose related 
manner. Iron (II) functions as a lipid peroxidant by forming hydroxyl radicals via the 
Fenton reaction. Because phenytoin is not a good free radical quencher as found from 
chapter 3, it can be speculated that possible interaction between the drug and iron might 
be occurring and thereby preventing the generation of the potent damage causing 
hydroxyl radicals. 
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7.4. CHAPTER 5:  Iron binding studies  
 
Phenytoin’s ability to bind/chelate iron (II) and iron (III) ions was examined using 
ultraviolet (UV), electrochemical analysis and infrared (IR) spectroscopy. The UV results 
indicate a small shift of the phenytoin major peaks from 200.8 nm to 211.0 nm and 210.9 
nm with iron (II) and iron (III) respectively. Furthermore the colour changes observed 
while adding phenytoin to the iron (II) solution indicates that iron (II) is getting oxidised 
to iron (III) before the latter binds to phenytoin. Essentially, this experiment suggests that 
there exists an interaction between iron ions and phenytoin. 
 
In the electrochemical study, the ASV of phenytoin and iron (II) from Figure 5.2. 
indicates a weak metal-ligand interaction between Fe2+ and phenytoin. This was because 
there was a shift to less negative potentials, indicating that the metal-ligand species is 
easier to reduce than the metal alone. When the experiment was repeated using iron (III) 
and phenytoin, the decrease in current response as shown in Figure 5.3 may indicate that 
the Fe3+ is bound in a form, which is not easily reduced by the ligand. However, the lack 
of a potential shift does not support this theory and therefore the interaction of Fe3+ and 
phenytoin in this study is inconclusive. 
 
The infrared studies indicated splitting and shifting of peaks in the region representing 
the NH functional group. This suggests that coordination might be taking place at the NH 
functional group or that there has been a change in the chemical environment of the 
functional group on the phenytoin molecule after interacting with the metal ions. 
Moreover the graphs obtained with the Fe (II)–phenytoin and Fe (III)- phenytoin were 
not different and could be almost superimposed indicating that the product formed were 
similar.  This suggests that iron (II) is being maintained in its oxidised form, that is its 
iron (III) form that is less toxic and that might have been the reason why there was a 
significant dose related reduction when iron (II) was used as a lipid peroxidant. 
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7.5. CHAPTER 6:   Phenytoin and its interaction with the pineal 
gland. 
 
This study was performed in order to assess if phenytoin can cause the pineal gland to 
augment the synthesis of melatonin, a powerful endogenous antioxidant. This was done 
using a combination of techniques consisting of organ culture, thin layer chromatography 
and scintillometry. It was found that phenytoin does not increase melatonin production 
but in fact shows a non-significant reduction in the levels of the pineal hormone even 
though the level of its precursor, NAS, was found to be higher in the phenytoin treated 
rats. This could be due to the fact that phenytoin might be interacting with the enzyme 
HIOMT, which is responsible for the O-methylation of NAS to form MEL, in some 
manner that may be reducing its activity. 
 
7.6. FINAL CONCLUSION 
 
In this thesis, some of the possible neuroprotective properties of phenytoin were 
investigated. The histological study of the CA1 and CA3 regions of the 
hippocampus under the insult of QUIN, with or without pre-treatment with 
phenytoin revealed that this agent confers protection in these regions. Because 
QUIN is believed to mediate neurotoxicity via a free radical mechanism, the 
effects of phenytoin on free radicals were tested. These studies were done using 
the NBT assay which assays for superoxide anions and lipid peroxidation assay 
which measures the amount of MDA produced. Phenytoin does not reduce KCN-
induced superoxide generation and QUIN-induced lipid peroxidation, but however 
there was a dose-dependent decrease of lipid peroxidation when induced with iron 
(II) as neurotoxin because of a probable interaction between phenytoin and iron 
(II). In order to shed more light on this possible interaction, metal binding studies 
with iron (II) and iron (III) were performed using UV, IR and electrochemical 
analysis. These studies point out that this interaction between phenytoin and iron 
may be occurring through the Nitrogen atom on the phenytoin molecule and it is 
possible that this perceived interaction is related to the observed reduction in lipid 
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peroxidation in the presence of iron (II). The effect of phenytoin on levels of 
endogenous antioxidant, melatonin, was also established. Phenytoin does not 
increase melatonin production, but slightly and non-significantly reduces the 
levels of this pineal hormone. 
 
7.7. FUTURE RECOMMENDATIONS 
 
The effect of phenytoin on live cultured neurons should be performed in order to see 
whether it could reduce neuronal damage by lipid peroxidation with quinolinic acid. 
Moreover the effect of phenytoin on the different enzymes in the kynurenine pathway, 
which are responsible for the synthesis of QUIN, should be performed to see whether this 
drug could reduce the level of this neurotoxin. 
 
Further studies using techniques such as nuclear magnetic resonance, computer 
modelling studies and elemental analysis can be performed to determine the number of 
phenytoin molecule binding to iron and confirm the exact site where coordination is 
occurring so that more can be learnt about this interaction which is essential as iron has 
been reported to contribute towards numerous neurodegenerative diseases. 
 
Considering the fact that phenytoin has been a popular drug, in the treatment of epilepsy, 
for decades, with moderate success and given the knowledge that high levels of free 
radicals are generated during such an attack, it is important that the effects of co 
administering with an antioxidant on neurodegenerative processes be examined. 
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APPENDIX 2 
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